<SEC-DOCUMENT>0001140361-19-021082.txt : 20191121
<SEC-HEADER>0001140361-19-021082.hdr.sgml : 20191121
<ACCEPTANCE-DATETIME>20191121090620
ACCESSION NUMBER:		0001140361-19-021082
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20191121
DATE AS OF CHANGE:		20191121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-221421
		FILM NUMBER:		191235867

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>nt10005799x3_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<html>
<head>
    <title> </title>
 <meta content="text/html; charset=UTF-8">
 <meta name="GeneratedBy" content="Summit Financial Printing, LLC" version="1.32">
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 6.5.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body>
<!-- 100-cov -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: right; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Filed Pursuant to Rule 424(b)(5)<br></b><b>Registration No. 333-221421</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 80px; margin-bottom: 0px; ">Prospectus supplement<br>(To prospectus dated December 12, 2017)</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; "><img src="logo_biocryst2a.jpg" alt="" style="height: 114.40px; width: 281.60px; scale: ">&#8201;<br></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 18px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; "><i><b>Pre-Funded Warrants to Purchase 11,764,706 Shares of Common Stock </b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to this prospectus supplement and the accompanying prospectus, BioCryst Pharmaceuticals, Inc. is offering warrants to purchase up to 11,764,706 shares of our common stock to the investors at a price of $1.69 per warrant. We refer to these warrants as pre-funded warrants. Each pre-funded warrant will have an exercise price of $0.01 per share. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of these pre-funded warrants. We are not paying underwriting discounts or commissions, so the proceeds to us, before expenses, will be approximately $19.9 million, excluding any proceeds we may receive upon the exercise of the pre-funded warrants. We estimate that our total expenses of this offering will be approximately $100,000. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;BCRX.&#148; On November 19, 2019, the last reported sale price of our common stock on the Nasdaq Global Select Market was $2.03 per share. We do not intend to list the pre-funded warrants on the Nasdaq Global Select Market or any other national securities exchange or any other nationally recognized trading system.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Investing in our securities involves risks. See &#147;Risk F</b><b>actors&#148; on page S-</b><b><a href="#sRF">6</a></b><b> of this prospectus supplement and in the documents </b><b>incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the factors </b><b>you should carefully consider before deciding to purchase our securities.</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these </b><b>securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus.</b><b> Any </b><b>representation to the contrary is a criminal offense.</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Delivery of the pre-funded warra nts is expected to be made on November 21, 2019. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The date of this Prospectus Supplement is November 19, 2019.</p>
			<div style="clear: both;"></div></div>





<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 101-toc -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>TABLE OF CONTENTS</b></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>PROSPECTUS SUPPLEMENT</b></p>
				<a name="TOC"></a><table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.71px; padding-right: 0px; "><b>Page</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sABOUT">ABOUT THIS PROSPECTUS SUPPLEMENT</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sABOUT">S-ii</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sFLS">FORWARD-LOOKING STATEMENTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sFLS">S-iii</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sPSS">PROSPECTUS SUPPLEMENT SUMMARY</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sPSS">S-1</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sOFF">THE OFFERING</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sOFF">S-5</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sRF">RISK FACTORS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sRF">S-6</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sUOP">USE OF PROCEEDS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sUOP">S-29</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sDIL">DILUTION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sDIL">S-30</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sDOS">DESCRIPTION OF PRE-FUNDED WARRANTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sDOS">S-31</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sPOD">PLAN OF DISTRIBUTION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sPOD">S-32</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sLEGAL">LEGAL MATTERS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sLEGAL">S-33</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sEXP">EXPERTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sEXP">S-33</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sWYCFMI">WHERE YOU CAN FIND MORE INFORMATION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sWYCFMI">S-33</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.71px; "><a href="#sINC">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#sINC">S-33</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>PROSPECTUS</b></p>
				<a name="TOC"></a><table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; ">&#160;</div></td>
	<td colspan="3" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.52px; padding-right: 0px; "><b>Page</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pATP">ABOUT THIS PROSPECTUS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pATP">i</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pPS">PROSPECTUS SUMMARY</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pPS">1</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pRF">RISK FACTORS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pRF">2</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pIRS">INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pIRS">3</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pUOP">USE OF PROCEEDS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pUOP">5</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pDPD">DESCRIPTION OF COMMON STOCK, PREFERRED STOCK AND DEPOSITARY SHARES</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pDPD">6</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pDPC">DESCRIPTION OF STOCK PURCHASE CONTRACTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pDPC">9</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pDOW">DESCRIPTION OF WARRANTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pDOW">10</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pDOU">DESCRIPTION OF UNITS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pDOU">11</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pPOD">PLAN OF DISTRIBUTION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pPOD">12</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pLM">LEGAL MATTERS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pLM">15</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pEXP">EXPERTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pEXP">15</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pWFI">WHERE YOU CAN FIND MORE INFORMATION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pWFI">16</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pICR">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pICR">16</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-i</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sABOUT"></a><b>ABOUT THIS PROSPECTUS SUPPLEMENT</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This document is part of a registration statement that we filed with the Securities and Exchange Commission (the &#147;SEC&#148;) using a &#147;shelf&#148; registration process and consists of two parts. The first part is the prospectus supplement, which describes the specific terms of this offering of securities and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus, or the base prospectus, dated December 12, 2017, including the documents incorporated by reference therein, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. You should read both this prospectus supplement and the accompanying prospectus, together with the additional information described under the caption &#147;Where You Can Find More Information&#148; below.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have not authorized anyone to provide you with information different from that contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus or any free writing prospectus prepared by us or on our behalf. We take no responsibility for, and can provide no assurances as to the reliability of, any information other than the information contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus or any free writing prospectus prepared by us or on our behalf. We are not offering to sell, nor seeking offers to buy, securities in any jurisdiction where an offer or sale is prohibited. You should assume that the information appearing in or incorporated by reference into this prospectus supplement, the accompanying prospectus or any free writing prospectus prepared by us or on our behalf is accurate or complete only as of their respective dates or on the date or dates which are specified in such documents, and that any information in documents that we have incorporated by reference is accurate or complete only as of the date of such document incorporated by reference. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. In addition, assumptions and estimates of our and our industry&#146;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors&#148; in this prospectus supplement, the accompanying prospectus and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2019, June 30, 2019 and September 30, 2019, each of which is incorporated by reference into this prospectus supplement. These and other important factors could cause our future performance to differ materially from our assumptions and estimates. See &#147;Forward-Looking Statements.&#148;</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the information set forth in this prospectus supplement, on the one hand, differs in any way from the information set forth in the accompanying prospectus or in a document which is incorporated by reference herein or therein that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information set forth in this prospectus supplement. If any statement in one of these documents conflicts with a statement in another document having a later date (for example, a document incorporated by reference in this prospectus supplement or in the accompanying prospectus), the statement in the document having the later date modifies or supersedes the earlier statement.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectus supplement and the accompanying prospectus to &#147;BioCryst,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to BioCryst Pharmaceuticals, Inc. together with its consolidated subsidiaries.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-ii</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sFLS"></a><b>FORWARD-LOOKING STATEMENTS</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus supplement and the accompanying prospectus, including the information we incorporate by reference, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), which are subject to the &#147;safe harbor&#148; created in Section 21E. All statements other than statements of historical facts contained in this prospectus supplement, the accompanying prospectus and the information we incorporate herein and therein by reference are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;believes,&#148; &#147;anticipates,&#148; &#147;expects,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. These forward-looking statements include, but are not limited to, statements about:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the preclinical development, clinical development, commercialization, or post-marketing studies of our product candidates and products, including our prophylactic and acute hereditary angioedema (&#147;HAE&#148;) programs, BCX9930, BCX9250, peramivir, galidesivir, and early stage discovery programs;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the potential funding from our contracts with the Biomedical Advanced Research and Development Authority (the &#147;BARDA/HHS&#148;) and the National Institute of Allergy and Infectious Diseases (&#147;NIAID/HHS&#148;) for the development of galidesivir;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the potential for government stockpiling orders of peramivir and galidesivir, additional regulatory approvals of peramivir, or milestones, royalties or profit from sales of peramivir by us or our partners;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the potential use of peramivir as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to establish and maintain collaborations or out-license rights to our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the outcome, cost and timing of any resolution of disputes and legal proceedings, including but not limited to the dispute with our partner Seqirus UK Limited (&#147;SUL&#148;);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">plans, programs, progress and potential success of our collaborations, including SUL for peramivir, Mundipharma International Holdings Limited (&#147;Mundipharma&#148;) for mundesine, Torii for BCX7353 in Japan and Shionogi and Green Cross Corporation (&#147;Green Cross&#148;) for peramivir in their territories;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">our ability, and the ability of our consolidated subsidiary, MDCP, LLC, to satisfy obligations under our secured loan facility with MidCap Financial, a Delaware statutory trust, pursuant to the terms and conditions of the Second Amended and Restated Credit and Security Agreement dated as of February 5, 2019, as amended (the &#147;Senior Credit Facility&#148;);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the ability of our wholly owned subsidiary, JPR Royalty Sub LLC (&#147;Royalty Sub&#148;) to service its payment obligations in respect of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#147;PhaRMA Notes&#148;);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes (the &#147;Currency Hedge Agreement&#148;);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to operate our business without infringing the intellectual property rights of others;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">estimates of our expenses, revenues, capital requirements, annual cash utilization, and our needs for additional financing;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to continue as a going concern;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the timing or likelihood of entering into additional U.S. government stockpile orders and our ability to execute all such orders;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to raise additional capital to fund our operations or repay our recourse debt obligations;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-iii</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to comply with the covenants as set forth in the agreements governing our debt obligations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our financial performance;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the timing and success of our anticipated commercialization of BCX7353 in the U.S. and elsewhere; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">competitive companies, technologies and our industry.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#147;Risk Factors&#148; and elsewhere in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Discussions containing these forward-looking statements are also included in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; incorporated by reference from our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2019, June 30, 2019 and September 30, 2019, and our Current Reports on Form 8-K, as well as any amendments we make to those filings with the SEC.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-iv</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 102-sum -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sPSS"></a><b>PROSPECTUS SUPPLEMENT SUMMARY</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>This summary highlights information contained elsewhere or incorporated by reference in this prospectus </i><i>supplement, the accompanying prospectus or any free writing prospectus prepared by us or on our behalf and does </i><i>not contain all of the information that you should consider before investing in our securities. You should read this </i><i>entire prospectus supplement and the accompanying prospectus carefully, including the </i><i>&#147;Risk Factors&#148;</i><i> section of this </i><i>prospectus supplement beginning on page S-6 and the consolidated financial statements and related notes and other </i><i>information incorporated by reference in this prospectus supplement and the accompanying prospectus, before </i><i>making an investment decision.</i></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>BioCryst Pharmaceuticals, Inc.</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a biotechnology company that discovers novel, oral, small-molecule medicines. We focus on oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. We integrate the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. Structure-guided drug design is a drug discovery approach by which we design synthetic compounds from detailed structural knowledge of the active sites of enzyme targets associated with particular diseases. We use X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Enzymes are proteins that act as catalysts for many vital biological reactions. Our goal generally is to design a compound that will fit in the active site of an enzyme and thereby prevent its catalytic activity. Molecules from our discovery efforts which are commercially available or that are in active development are summarized in the table below:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="17%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>Drug/Drug<br></b><b>Candidate</b></div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>Drug Class</b></div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>Therapeutic<br></b><b>Area(s)</b></div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>Phase</b></div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 0px; "><b>Rights</b></div>
							</td>
						</tr>


						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">RAPIVAB<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><br>(peramivir injection)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Intravenous Neuraminidase Inhibitor</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Acute uncomplicated Influenza</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Approved (U.S., Australia &amp; Canada)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Seqirus (worldwide, except Japan, Korea, Taiwan and Israel) BioCryst retains full U.S. Government stockpiling rights</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">ALPIVAB<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> (peramivir injection)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Intravenous Neuraminidase Inhibitor</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Acute uncomplicated Influenza</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Approved (European Union)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Seqirus (worldwide, except Japan, Korea, Taiwan and Israel)</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">RAPIACTA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (peramivir injection)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Intravenous Neuraminidase Inhibitor</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Uncomplicated seasonal influenza</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Approved (Japan &amp; Taiwan)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Shionogi (Japan &amp; Taiwan)</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">PERAMIFLU<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (peramivir injection)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Intravenous Neuraminidase Inhibitor</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Uncomplicated seasonal influenza</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Approved (Korea)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Green Cross (Korea)</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">BCX7353</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Oral Serine Protease Inhibitor Targeting Plasma Kallikrein (once-daily treatment) </div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Hereditary Angioedema (&#147;HAE&#148;)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Phase 3 </div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">BioCryst (worldwide, except Japan) Torii Pharmaceutical Co., Ltd. (Japan) </div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Oral dose formulation for acute treatment</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Phase 3</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">BioCryst (worldwide)</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-1</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="17%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>Drug/Drug<br></b><b>Candidate</b></div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>Drug Class</b></div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>Therapeutic<br></b><b>Area(s)</b></div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>Phase</b></div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 0px; "><b>Rights</b></div>
							</td>
						</tr>


						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">BCX9930</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Oral Factor D Inhibitor</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Complement- mediated diseases</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Phase 1</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">BioCryst (worldwide)</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">BCX9250</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Activin Receptor-Like Kinase-2 (&#147;ALK-2&#148;) Inhibitors</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Fibrodysplasia Ossificans Progressiva (&#147;FOP&#148;)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Phase 1</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">BioCryst (worldwide)</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Galidesivir<br>(formerly BCX4430)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">RNA dependent-RNA Polymerase Inhibitor</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Broad spectrum antiviral for 20 RNA viruses, including Marburg, Yellow Fever, and Ebola</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Phase 1</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">BioCryst (worldwide)</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Mundesine&#174; (forodesine)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Oral Purine Nucleoside Phosphorylase Inhibitor</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Oncology - PTCL</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Approved (Japan)</div>
							</td>
							<td width="20%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Mundipharma (worldwide)</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Business Strategy</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our business strategy is to create shareholder value by focusing our discovery and development efforts on oral drugs for rare diseases for which a significant unmet medical need exists. We select disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market. We strive to advance our product candidate portfolio from discovery to commercial markets efficiently by utilizing a small group of talented and highly-skilled employees working in conjunction with strategic outsource partners. BioCryst is unique in its approach to treat orphan diseases with orally-administered, small molecules utilizing crystallography and structure-guided drug design. The principal elements of our strategy are:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; "><i>Focusing on High Value-Added Structure-Guided Drug Design Technologies. </i>We utilize structure-guided drug design in order to most efficiently develop new therapeutic candidates. Structure-guided drug design is a process by which we design a product candidate through detailed analysis of the enzyme target, which the product candidate must inhibit in order to stop the progression of the disease or disorder. We believe that structure-guided drug design is a powerful tool for the efficient development of small-molecule product candidates that have the potential to be safe and effective. Our structure-guided drug design technologies typically allow us to design and synthesize multiple product candidates that inhibit the same enzyme target, with the goal of establishing broad patent protection and formulating compounds with competitive advantages.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; "><i>Selecting Inhibitors that are Promising Product Candidates. </i>We start by selecting disease targets with well-understood biology and characteristics that fit with our ability to utilize structure-guided drug design capabilities to build potent and specific enzyme inhibitors. Next, we narrow our selection of these product candidates based on product characteristics, such as initial indications of safety and biologic activity on the target.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; "><i>Developing our Product Candidates Efficiently. </i>An important element of our business strategy is to efficiently progress our product candidates through the development process. In order to accomplish this, we typically strive for disease targets with a defined clinical and regulatory pathway for approval. In addition, we control fixed costs and overhead by outsourcing with strategic partners and contractors or entering into license agreements with third parties, including the U.S. Government. We maintain a streamlined corporate infrastructure that focuses our expertise. By contracting with the U.S. Government and outsourcing certain aspects of our operations, we are able to control overhead costs and focus financial resources directly where they provide the most benefit and reduce our business risk.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-2</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Commercialization Activity</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We currently intend to submit a new drug application for BCX7353 with the U.S. Food and Drug Administration before the end of 2019, and to submit a new drug application in Japan and a marketing authorization application in the EU in early 2020. In anticipation of a commercial launch of BCX7353, we are in the process of developing our business infrastructure, personnel, partnerships, and marketing strategies to position BCX7353 for success in the commercial market, which we anticipate&#8212;based on proprietary market research, including analyses of HAE prevalence in the U.S. and market research studies with HAE patients, physicians, and payors in the U.S.&#8212;has the potential to reach a global peak of over $500 million in annual sales. These expectations are subject to numerous risks and uncertainties that may cause our actual results, performance or achievements to be materially different. There can be no assurance that regulatory approval of BCX7353 will be granted in a timely fashion or at all, that our commercialization methods and strategies will succeed, or that the market for BXC7353 will develop in line with our current expectations. See &#147;Risk Factors&#148; beginning on page S-6, including the information under &#147;Risk Factors&#8212;We do not have a great deal of experience in commercializing our products or technologies, and our future revenue generation is uncertain,&#148; and the other information included in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus for further discussion of these risks.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Recent Developments</b></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Common Stock Offering</i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On November 18, 2019, we issued 43,620,690 shares of our common stock in a public offering (the &#147;Common Stock Offering&#148;). Total gross proceeds from the Common Stock Offering to the Company were $63.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>BCX9930 Phase 1 Results</i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On October 28, 2019, we announced interim results from an ongoing Phase 1 trial of BCX9930, our oral Factor D inhibitor. The interim results from the first eight cohorts enrolled in the trial showed that BCX9930 was safe and generally well tolerated, and showed rapid, sustained >95% suppression of the alternative pathway of the complement system at 100 mg every 12 hours in healthy subjects. Based on these results, we have decided to complete the multiple ascending dose component of the trial as well as to advance the program into a proof of concept study in paroxysmal nocturnal hemoglobinuria (&#147;PNH&#148;) patients (part 3 of the trial).</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>BCX9250 Phase 1 Trial</i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On November 1, 2019, we announced that we had begun a Phase 1 clinical trial with BCX9250, an oral ALK-2 inhibitor discovered and developed by us for the treatment of FOP. The Phase 1 trial will evaluate single and multiple ascending doses of oral BCX9250 in healthy volunteers.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>BCX7353 Commercialization and License Agreement</i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On November 5, 2019, we announced that we had entered into a Commercialization and License Agreement (the &#147;Torii Agreement&#148;) with Torii Pharmaceutical Co., Ltd. (&#147;Torii&#148;), granting Torii the exclusive right to commercialize BCX7353 in Japan for the prevention of HAE attacks. Under the Torii Agreement, we will receive an upfront, non-refundable payment of $22 million and may be eligible to receive an additional milestone payment of either $20 million if Japan&#146;s Pharmaceuticals and Medical Devices Agency (the &#147;PMDA&#148;) grants regulatory approval on or before December 31, 2020, or $15 million if regulatory approval is granted on or before December 31, 2021. In either case, the regulatory milestone payment is contingent upon receipt of a reimbursement price approval from Japan&#146;s National Health Insurance system in excess of the threshold specified in the Torii Agreement. In addition, we will be entitled to receive tiered royalty payments based on the amount of annual net sales of BCX7353 in Japan during each calendar year. If BCX7353 maintains its Sakigake designation during the PMDA review, the tiered royalty rate will range from twenty percent to forty percent of net sales, otherwise, the tiered royalty rate will range from fifteen percent to thirty-five percent of net sales.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-3</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 18%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a Delaware corporation originally founded in 1986. Our corporate headquarters is located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703 and the corporate telephone number is (919) 859-1302. For more information about us, please visit our website at www.biocryst.com. The information on our website is not incorporated by reference into this prospectus supplement or the accompanying base prospectus and does not constitute a part of this prospectus supplement or the accompanying base prospectus.</p>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-4</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sOFF"></a><b>THE OFFERING</b></p>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Pre-funded warrants offered</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-bottom: 0px; ">We are offering pre-funded warrants to purchase up to 11,764,706 shares of our common stock in this offering. Each pre-funded warrant will have an exercise price of $0.01 per share and will be exercisable upon issuance. The offering price for the pre-funded warrants is $1.69 per warrant. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of these pre-funded warrants.</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 298.67px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 13.33px; text-indent: -13.33px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Common stock to be outstanding after the<br> </b><b>offering</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-bottom: 0px; ">154,059,115 shares of common stock (this excludes any shares of common stock issuable upon exercise of the pre-funded warrants).</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Use of proceeds</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-bottom: 0px; ">We intend to use the net proceeds of this offering for general corporate purposes, which may include, but are not limited to: </div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="320px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">worldwide development, manufacturing, regulatory and commercial activities for the prophylactic BCX7353 program, primarily focusing on the U.S., EU and Japan;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="320px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">development of the BCX9930 program; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="320px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">development of the BCX9250 program; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="320px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">post-approval commitments for<br> RAPIVAB<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>/ALPIVAB<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="320px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">funding clinical development of pipeline assets; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="320px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">capital expenditures and other general corporate expenses. See &#147;Use of Proceeds.&#148;</td></tr></table><div style="clear: both"></div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Nasdaq global select market symbol</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">BCRX</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Risk factors</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-bottom: 0px; ">See &#147;Risk Factors&#148; beginning on page S-<a href="#sRF">6</a> and the other information included in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus for a discussion of certain factors you should carefully consider before deciding to invest in this offering.</div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The number of shares of our common stock to be outstanding after this offering is based on 154,059,115 shares outstanding as of November 19, 2019 and excludes:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">17,980,904 shares of common stock issuable upon the exercise of stock options outstanding under our Stock Incentive Plan and 1,166,724 shares of common stock issuable upon the exercise of stock options outstanding under our Inducement Equity Incentive Plan as of November 19, 2019, at a weighted average exercise price of $6.53 per share and $3.69 per share, respectively; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">4,064,450 additional shares of common stock reserved for issuance under our Stock Incentive Plan, 333,276 additional shares of common stock reserved for issuance under our Inducement Equity Incentive Plan, and 119,194 additional shares of common stock reserved for issuance under our Employee Stock Purchase Plan as of November 19, 2019.</td></tr></table><div style="clear: both"></div>
			</div><div style="clear: both"></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-5</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 103-risk -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sRF"></a><b>RISK FACTORS</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>An investment in our securities involves risks. You should consider carefully all of the information that is included </i><i>or incorporated by reference in this prospectus supplement and the accompanying prospectus before investing in our </i><i>securities. In particular, you should evaluate the uncertainties and risks referred to or described below, which may </i><i>adversely affect our business, financial condition, liquidity, results of operations, or prospects, along with all of the </i><i>other information included in our other filings with the SEC, before deciding to buy our securities.</i></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Relating </b><b>t</b><b>o </b><b>o</b><b>ur Business</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>We have incurred losses since our inception, expect to continue to incur such losses, and may never be profitable. </b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since our inception, we have not achieved sustained profitability. We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development efforts and commercial activities progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To become profitable, we, or our collaborative partners, must successfully manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future license agreements or revenues directly from product sales.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because of the numerous risks and uncertainties associated with developing our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our success depends upon our ability to advance our products through the various stages of development, </b></i><i><b>especially through the clinical trial process.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To receive the regulatory approvals necessary for the sale of our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate is safe and effective. The development process and related regulatory process are complex and uncertain. Because of the cost and duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. BCX7353, BCX9930, BCX9250 and galidesivir), even after earlier clinical trials show promising results. The development of our product candidates, including our clinical trials, may not be adequately designed or executed, which could affect the potential outcome and analysis of study results. Any of our product candidates may produce undesirable side effects in humans. Any of our product candidates, including BCX7353, BCX9930, galidesivir and BCX9250, may indicate or produce undesirable or inconclusive data in our pre-clinical and clinical studies. The pre-clinical data (including without limitation carcinogenicity, drug-drug interaction studies and toxicity studies) and clinical data from our product candidates, including BCX7353, BCX9930, galidesivir and BCX9250, could cause us or regulatory authorities to interrupt, delay, modify or halt preclinical or clinical trials of a product candidate or may result in restrictions or warnings that could impact development and the ultimate commercial outcome for a product candidate. Undesirable or inconclusive data or side effects in humans could also result in the U.S. Food and Drug Administration (the &#147;FDA&#148;) or foreign regulatory authorities refusing to approve the product candidate for any targeted indications or require restrictions or warnings that could impact development or the ultimate commercial success for a product candidate. In addition, the FDA or other regulatory agencies may determine that study data from our product candidates necessitates additional studies or study designs which differ from our planned development strategy, and regulatory agencies may also require patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost and timing of our planned development strategy. We, our partners, the FDA or foreign regulatory authorities may suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks. Pre-clinical studies (including without limitation carcinogenicity, drug-drug interaction studies and toxicity studies) and clinical trials for our product candidates, including BCX7353, BCX9930, galidesivir and BCX9250, and the overall analysis of the balance of safety and efficacy may fail to demonstrate that our product candidates are safe or effective, which could limit or eliminate the expected commercial viability of those product candidates. Regulatory authorities may interrupt, delay or halt clinical trials for a product candidate for any number of reasons.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-6</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ability to successfully complete clinical trials is dependent upon many factors, including but not limited to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to find suitable clinical sites and investigators to enroll patients;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the ability to maintain contact with patients to provide complete data after treatment;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our product candidates may not prove to be either safe or effective;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">manufacturing or quality control problems could affect the supply of product candidates for our trials; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">delays or changes in our planned development strategy, the regulations or guidelines, or other unexpected conditions or requirements of government agencies.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Clinical trials are lengthy and expensive. We or our partners incur substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that the tests and trials will ever result in the commercial sale of a product. For example, clinical trials require adequate supplies of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment, including for APeX-S, can result in increased costs and longer development times. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file the required regulatory submissions in a timely manner and may not receive regulatory approval for the product candidates.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We focus on rare diseases, which may create additional risks and challenges.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because we focus on developing drugs as treatments for rare diseases, we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the equivalent designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not to grant such designations. We cannot guarantee that we will be able to receive orphan drug status from the FDA or equivalent regulatory designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy or fast track designation, which may provide certain potential benefits such as more frequent meetings with the FDA to discuss the development plan, intensive guidance on an efficient drug development program, and potential eligibility for rolling review or priority review. Even if we are successful in obtaining any such designation by the FDA or other regulatory agency for our product candidates, such designations may not lead to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates will receive marketing approval. We may not be able to obtain or maintain such designations for our product candidates, and our competitors may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Although we have received Sakigake designation for BCX7353 in Japan, we may not experience a faster development, review or approval process compared to the conventional process, and we could lose the Sakigake designation.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our clinical trials may not adequately show that our product candidates are safe or effective.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Progression of our product candidates through the clinical development process is dependent upon our trials indicating our product candidates have adequate safety and efficacy in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve any of these endpoints in any of our programs, including BCX7353, BCX9930, BCX9250, galidesivir, and our other rare disease product candidates, could result in delays in our trials or require the performance of additional unplanned trials. This could result in delays in the development of our product candidates and could result in significant unexpected costs or the termination of programs.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-7</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If our development collaborations with third parties, such as our development partners, contractors and contract </b></i><i><b>research organizations, fail, the development of our product candidates will be delayed or stopped.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We rely heavily upon third parties for many important stages of our product candidate development, including but not limited to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">discovery of natural proteins that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">execution of certain pharmacology preclinical studies and late-stage development for our compounds and product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">management of our Phase 1, 2 and 3 clinical trials, including medical monitoring and data management;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">execution of toxicology studies that may be required to obtain approval for our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">formulation improvement strategies and methods; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our failure to engage in successful collaborations at any one of these stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting materials, drug substance and product candidates or assist with our regulatory function breached their obligations to us or perform their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent both the development of our product candidates and the availability of any potential commercial product.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to applicable FDA Good Laboratory Practices, Good Manufacturing Practices (&#147;cGMP&#148;) and current Good Clinical Practices, and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could be materially adversely affected.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Because we have limited manufacturing experience, we depend on third-party manufacturers to manufacture our </b></i><i><b>product, product candidates and the materials for our product candidates. Often, especially early in the </b></i><i><b>development and commercialization process, we have only one source for manufacturing. If we cannot rely on </b></i><i><b>existing third-party manufacturers, we will be required to incur significant costs and potential delays in finding </b></i><i><b>new third-party manufacturers.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have limited manufacturing experience and only a small scale manufacturing facility. We currently rely upon a very limited number of third-party manufacturers to manufacture the materials required for our product, product candidates and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party manufacturers to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party manufacturers, which may be the only manufacturer we have engaged for a particular product, may encounter difficulties with meeting our requirements, including but not limited to problems involving:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">inconsistent production yields;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">product liability claims or recalls of commercial product;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">difficulties in scaling production to commercial and validation sizes;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">interruption of the delivery of materials required for the manufacturing process;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">scheduling of plant time with other vendors or unexpected equipment failure;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-8</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">potential catastrophes that could strike their facilities or have an effect on infrastructure;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">poor quality control and assurance or inadequate process controls; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies or local customs, particularly associated with peramivir, BCX7353, BCX9930, BCX9250, galidesivir and our early stage compounds.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These contract manufacturers may not be able to manufacture the materials required for our product candidates at a cost or in quantities necessary to make them commercially viable. We also have no control over whether third-party manufacturers breach their agreements with us or whether they may terminate or decline to renew agreements with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#146;s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or similar foreign regulatory agencies may at any time implement new standards, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties any of which could be costly to us and could result in a delay or shortage of product.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are unable to maintain current manufacturing or other contract relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers, we may not be able to complete development of, seek timely approval of, or market, our product candidates.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our raw materials, drug substances, and product candidates are manufactured by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items, this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We face intense competition, and if we are unable to compete effectively, the demand for our products, if any, may </b></i><i><b>be reduced.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The biotechnology and pharmaceutical industries are highly competitive and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing of potential product candidates for desirable disease targets, licensing of desirable product candidates, and development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition may also arise from, among other things:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">other drug development technologies;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">methods of preventing or reducing the incidence of disease, including vaccines; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">new small molecule or other classes of therapeutic agents.</td></tr></table><div style="clear: both"></div>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Developments by others may render our product candidates or technologies obsolete or noncompetitive.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are performing research on or developing products for the treatment of several rare diseases, including HAE, FOP and diseases of the complement system, as well as developing broad spectrum antivirals for use as medical </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-9</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">countermeasures. We expect to encounter significant competition for any of the pharmaceutical products we are developing and plan to develop. Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive advantage. Such is the case with the current neuraminidase inhibitors marketed by GlaxoSmithKline plc and F. Hoffmann-La Roche Ltd. for influenza; CINRYZE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, KALBITOR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, FIRAZYR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, TAKHZYRO&#8482; and generic icatibant marketed by Takeda Pharmaceutical Company, Ltd., for HAE; BERINERT<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and HAEGARDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, marketed by CSL Limited (&#147;CSL&#148;) for HAE; RUCONEST<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, marketed by Pharming Healthcare, Inc. for HAE; icatibant, distributed by Teva Pharmaceutical Industries, Ltd. (&#147;Teva&#148;) for HAE; and SOLIRIS&#174; and ULTOMIRIS&#8482;, marketed by Alexion Pharmaceuticals, Inc. for PNH, atypical hemolytic uremic syndrome, and myasthenia gravis.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Further, several pharmaceutical and biotechnology firms have announced efforts in HAE and in other therapeutic areas where we have discovery and development efforts ongoing. KalVista Pharmaceuticals, Inc. has announced plans to conduct a Phase 2 clinical trial in 2019 of an oral kallikrein inhibitor (KVD900) as a treatment for acute attacks. KalVista (KVD824) and Attune Pharmaceuticals, Inc. (ATN-249) also have oral kallikrein inhibitors in Phase 1 clinical trials and Pharvaris (PHA121) has an oral B2 bradykinin antagonist in preclinical development that may be developed as treatments for HAE. CSL has an anti-factor XII Mab (CSL312) in Phase 2 clinical development in HAE patients. The drug substance patent of Takeda&#146;s acute treatment, Firazyr, expired in July 2019. A generic icatibant from Teva and a branded generic icatibant from Takeda, have entered the therapeutic space, with a few other potential generic drug candidates in the pipeline. Currently, there are five investigational therapeutics under a compassionate use/expanded access framework that can be available in an outbreak setting to treat Ebola virus disease. In early 2018, Shionogi announced the approval in Japan of Xofluza, an oral treatment for influenza, which also received approval from the FDA in October of 2018. For FOP, Clementia Pharmaceuticals, acquired in April 2019 by Ipsen, is developing palovarotene, an oral therapy that is in Phase 2 and 3 trials; Regeneron Pharmaceuticals, Inc.&#146;s injectable REGN2477 is in Phase 2; and Blueprint Medicines Corporation&#146;s BLU-782, licensed by Ipsen, completed a Phase 1 trial in 2019. There are many additional potential competitors in PNH and other complement-mediated diseases. Achillion Pharmaceuticals Inc., Novartis AG and ChemoCentryx, Inc. all have oral complement inhibitors in Phase 2 or Phase 3 clinical trials. Apellis Pharmaceuticals Inc., Ra Pharmaceuticals, Inc., Akari Therapeutics, PLC, Regeneron Pharmaceuticals, Inc., and Omeros Corporation are also developing novel complement inhibitors that have reached Phase 2 or Phase 3 clinical trials. SOLIRIS is no longer under patent protection and one or more biosimilar versions of that product may be developed. If one or more of our competitors&#146; products or programs, including potential competitors not listed, are successful, the market for our products may be reduced or eliminated.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Compared to us, many of our competitors and potential competitors have substantially greater:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">capital resources;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">research and development resources, including personnel and technology;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulatory experience;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">preclinical study and clinical testing experience;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">manufacturing and marketing experience; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">production facilities.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any of these competitive factors could impede our funding efforts, render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We face risks related to our government-funded programs; if BARDA/HHS or NIAID/HHS were to eliminate, </b></i><i><b>reduce or delay funding from our contracts, this would have a significant negative impact on the programs </b></i><i><b>associated with such funding and could have a significant negative impact on our revenues and cash flows.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our projections of revenues and incoming cash flows are substantially dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our galidesivir program. If BARDA/HHS or NIAID/HHS were to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain additional funding for continued development or regulatory registration for these product candidates or significantly reduce or stop the development effort.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-10</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In contracting with BARDA/HHS and NIAID/HHS, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or if we are found to be in violation could result in contract termination. If the U.S. Government terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our government contracts with BARDA/HHS and NIAID/HHS have special contracting requirements, which </b></i><i><b>create additional risks of reduction or loss of funding.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have completed work under a contract with BARDA/HHS for the development of our neuraminidase inhibitor, RAPIVAB. We also have entered into contracts with BARDA/HHS and NIAID/HHS for the development of galidesivir as a treatment for diseases caused by RNA pathogens, including Marburg virus disease, Yellow Fever and Ebola virus disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation, could result in contract termination.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">U.S. Government contracts typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government to unilaterally:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">terminate or reduce the scope of our contract with or without cause;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">interpret relevant regulations (federal acquisition regulation clauses);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">require performance under circumstances which may not be favorable to us;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">require an in process review where the U.S. Government will review the project and its options under the contract;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">control the timing and amount of funding, which impacts the development progress of our programs; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">audit and object to our contract-related costs and fees, including allocated indirect costs.</td></tr></table><div style="clear: both"></div>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our government contracts with BARDA/HHS and NIAID/HHS have termination and audit provisions which </b></i><i><b>create additional risks to us.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The U.S. Government may terminate its contracts with us either for its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further, if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a U.S. Government contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and management information systems. Audits under the active BARDA/HHS and NIAID/HHS galidesivir contracts may occur at the election of the U.S. Government and have been concluded through fiscal 2015; all subsequent fiscal years are still open and auditable. Based on the results of its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-11</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">suspension of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under </b></i><i><b>our license agreements, our licensors may terminate our agreements with them and seek additional remedies.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are unable or fail to meet payment obligations, performance milestones relating to the timing of regulatory filings, product supply obligations, post-approval commitments for RAPIVAB, or development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in accordance with applicable provisions; or fail to pay the minimum annual payments under our respective licenses, our licensors may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate or commercialization of the product would cease. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we fail to obtain additional financing or acceptable partnership arrangements, we may be unable to complete </b></i><i><b>the development and commercialization of our product candidates or continue operations.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As our programs advance, our costs are likely to increase. Our current and planned discovery activities, pre-clinical and clinical trials, the related development, manufacturing, regulatory approval process requirements, and the additional personnel resources and testing required for supporting the development of our product candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements for our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for galidesivir or from other new partnerships with third parties for the development of our product candidates, including BCX7353, BCX9930, BCX9250 and our other rare disease product candidates; the commercial success of peramivir achieved by our partners; the amount or profitability of any orders for peramivir or galidesivir by any government agency or other party; the progress and results of our current and proposed clinical trials for our most advanced product candidates, including BCX7353, BCX9930, galidesivir, BCX9250 and our other rare disease product candidates; the progress made in the manufacture of our lead products and the progression of our other programs.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect that we will be required to raise additional capital to complete the development and commercialization of our current product candidates and we may seek to raise capital at any time. Additional funding, whether through additional sales of securities, additional borrowings, royalty or other monetization transactions, collaborative arrangements with partners, including governmental agencies in general and from any BARDA/HHS or NIAID/HHS contract specifically, or from other sources, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. Additional borrowings may subject us to more restrictive covenants than are currently applicable to us under our Senior Credit Facility. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate certain of our research and development programs.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In order to continue future operations and continue our drug development programs, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government funding, we may decide to access the equity or debt markets, incur additional borrowings, or seek other sources to meet liquidity needs. Our ability to raise additional capital may be limited and may greatly depend upon the success of ongoing development related to our current drug development programs, including post approval studies for RAPIVAB, the progress, timeline and ultimate outcome of development programs for our kallikrein inhibitors, such as BCX7353 (including, but not limited to, formulation progress, long-term human safety studies, and carcinogenicity, drug-drug interaction, toxicity, or other required studies), the progress of BCX9250 for the treatment of FOP, BCX9930 for diseases of the complement system and other rare disease product candidates. In addition, constriction and volatility in the equity and debt markets may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include investors, licensing partners, and the U.S. Government) which may be unstable </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-12</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">or may become unstable in the current economic and political environment. Any such instability may impact these parties&#146; ability to fulfill contractual obligations to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital or credit markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue development of our product candidates.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may not be able to continue as a going concern if we do not obtain additional capital.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have sustained operating losses for the majority of our corporate history and expect that our 2019 expenses will exceed our 2019 revenues. We expect to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our liquidity needs will be largely determined by the success of operations in regards to the progression of our product candidates in the future. Our plans to alleviate the doubt regarding our ability to continue as a going concern primarily include our ability to control the timing and spending on our research and development programs and raising additional funds through equity financings. We will consider the following plans to fund operations including: (1) securing or increasing U.S. Government funding of our programs, including obtaining additional government funding under and delivering on procurement contracts; (2) out-licensing rights to certain of our products or product candidates, pursuant to which the we would receive cash milestones and/or royalties; (3) raising additional capital through equity and/or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (5) reducing spending on research and development programs, including by discontinuing and suspending development; and/or (6) restructuring operations to change our overhead structure.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There can be no assurance that any of our plans will be successful or that additional capital will be available to us on reasonable terms, or at all, when needed. If we are unable to obtain sufficient additional capital, we may be forced to curtail operations, delay or stop ongoing clinical trials, cease operations altogether or file for bankruptcy.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we fail to successfully commercialize or establish collaborative relationships to commercialize certain of our </b></i><i><b>product candidates, or if any partner terminates or fails to perform its obligations under agreements with us, </b></i><i><b>potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our business strategy is to increase the asset value of our product candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development, regulatory approval, marketing, sales and distribution of our product candidates.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Currently, we have established collaborative relationships with Mundipharma for the development and commercialization of Mundesine, Torii for the commercialization of BCX7353 in Japan, and with each of SUL, Shionogi and Green Cross for the development and commercialization of peramivir on a worldwide basis. The process of establishing and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory commercial, regulatory or clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our contracts for collaborative arrangements may expire;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our partners may choose to pursue alternative technologies, including those of our competitors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">we may have disputes with a partner that could lead to litigation or arbitration, such as the ongoing arbitration proceeding between us and SUL, which could result in substantial costs and divert the attention of our management;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">we do not have day to day control over the activities of our partners and have limited control over their decisions;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-13</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we or our partners may not devote sufficient capital or resources towards our product candidates; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we or our partners may not comply with applicable government regulatory requirements.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we or our partners fail to fulfill our responsibilities in a timely manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further development of one or more of our product candidates, undertake commercialization activities at our own expense or find alternative sources of funding. Any delay in the development or commercialization of our product candidates would severely affect our business, because if our product candidates do not progress through the development process or reach the market in a timely manner, or at all, we may not receive additional future event payments and may never receive milestone, product sales or royalty payments.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The results of our partnership with Torii may not meet our current expectations.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have a commercialization agreement with Torii. We do not have a history of working with Torii and cannot predict the success of this collaboration. Our ability to realize the expected benefits of this collaboration, including with respect to the receipt or amounts of potential milestone or royalty payments, is subject to a number of risks, including that applicable regulatory agencies may not provide adequate regulatory clearances or reimbursement approvals on a timely basis or at all, the commercial potential of BCX7353 may not meet our current expectations, we or Torii may fail to comply with our respective obligations under the Torii Agreement, and third parties may fail to perform their obligations to us on a timely basis or at all.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Torii Agreement provides for potential milestone payments depending on the receipt and timing of regulatory approval and contingent upon receipt of a reimbursement price approval from Japan&#146;s National Health Insurance system in excess of the threshold specified in the Torii Agreement, either of which we may not receive on a timely basis or at all. The Torii Agreement also provides that we will be entitled to receive tiered royalty payments, the amounts of which will depend upon the amount of annual net sales of BCX7353 in Japan during each calendar year, whether BCX7353 maintains its Sakigake designation prior to the receipt of the first regulatory approval of BCX7353 for the prevention of HAE attacks in Japan, and other factors. We remain responsible for regulatory activities with respect to BCX7353 in Japan for one year after the first commercial sale. We expect to use third parties to satisfy many of our obligations under the Torii Agreement, including but not limited to our regulatory and other responsibilities in Japan. If our interactions, or those of our third party agents, are unsuccessful, we could fail to meet our obligations under the Torii Agreement, fail to receive regulatory approval of BCX7353 on a timely basis or at all, receive approval of BCX7353 on a narrower scope than currently anticipated, or fail to receive reimbursement authorization in excess of the specified threshold, which could negatively impact the commercial success and the partnership, impact the economic benefit expected or require additional development of BCX7353.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Torii may terminate the Torii Agreement under certain limited circumstances, including the receipt of notice that certain additional development activities are required for regulatory approval of BCX7353, if regulatory approval of BCX7353 is not received prior to December 31, 2022, or upon one year&#146;s written notice after the sixth anniversary of the first commercial sale of BCX7353 in Japan. If the Torii Agreement is terminated in connection with these provisions, we will no longer be entitled to receive any milestone or royalty payments thereunder, which could have a material adverse impact on our business and results of operations.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Torii will have sole control over and decision-making authority with respect to commercialization activities for BCX7353 for the prevention of HAE attacks in Japan, subject to oversight from a joint steering committee. Therefore, our receipt of, and the amounts of, any royalty payments under the Torii Agreement are dependent upon Torii&#146;s </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-14</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">successful performance of such commercialization activities. In addition, competitive products and variations in patient demand, prescription levels, reimbursement determinations or other factors may limit the commercial potential of BCX7353 in Japan, which could materially reduce the amount of any royalties we would be entitled to receive under the Torii Agreement.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Torii Agreement, we will be responsible for supplying Torii with its required amounts of BCX7353 for commercial sale. If due to the failure of our third-party contract manufacturers to produce sufficient drug product we fail to supply to Torii the required amounts of BCX7353, then Torii&#146;s ability to successfully commercialize BCX7353 in Japan could be materially impaired, and we may receive less royalty income under the Torii Agreement, or none at all.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any of the foregoing risks could materially adversely impact our ability to obtain regulatory approval of BCX7353 in Japan, the price of BCX7353 in Japan, and our ability to perform our obligations under the Torii Agreement, which could materially reduce the economic benefits of the Torii Agreement to us and impair or result in the termination of our collaboration with Torii.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We do not have a great deal of experience in commercializing our products or technologies, and our future </b></i><i><b>revenue generation is uncertain.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not have a great deal of experience in commercializing our product candidates or technologies. We currently have limited marketing and commercial capability, no direct or third-party sales force and limited distribution capabilities. We may be unable to establish or sufficiently increase these capabilities for products we currently, or plan to, commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status of our preclinical and clinical programs.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ability to receive revenue from products we commercialize presents several risks, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">we or our collaborators may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep applicable regulatory agency marketing approval;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reimbursement is constantly changing, which could greatly affect usage of our products; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have conducted our own proprietary market research to assess the market potential for BCX7353, including analyses of HAE prevalence in the United States and market research studies with selected HAE patients, physicians and payors in the United States. As part of our market research, we presented a blinded profile of BCX7353 to respondents based on 24-week efficacy and safety data from APeX-2 and an assumed product label. We cannot be certain that we will observe the same efficacy and safety results in our continued development of this product candidate, and even if we ultimately obtain regulatory approval for BCX7353, the resulting label may not be consistent with the profile utilized in our market research. In addition, the respondents in our market research may not reflect the views of the market as a whole, and the actual commercial potential for BCX7353 may be materially different than our current expectations.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-15</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Commercialization of peramivir by our partners is subject to the potential commercialization risks described </b></i><i><b>herein and numerous additional risks. Any potential revenue benefits to us in the form of milestone payments, </b></i><i><b>royalties or other consideration are highly speculative.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Commercialization success of peramivir is uncertain and is subject to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition, commercialization of peramivir products is subject to further risks and may be negatively impacted by a number of factors, including, but not limited to, the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">peramivir may not prove to be adequately safe and effective for market approval in markets other than the United States, Canada, Japan, Korea, Taiwan, Australia and the European Union;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">necessary funding for post-marketing commitments and further development of peramivir may not be available timely, at all, or in sufficient amounts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for peramivir;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">a limited number of governmental entities are expected to be the primary potential stockpiling customers for peramivir and if we are not successful at marketing peramivir to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for peramivir;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the commercial demand and acceptance for peramivir by healthcare providers and by patients may not be sufficient to result in substantial revenues of peramivir to our partners and may result in little to no milestones or royalties to us;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">effectiveness of marketing and commercialization efforts for peramivir by our partners;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">market satisfaction with existing alternative therapies;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">perceived efficacy relative to other available therapies;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">disease prevalence;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">cost of treatment;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">pricing and availability of alternative products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">marketing and sales activities of competitors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">shifts in the medical community to new treatment paradigms or standards of care; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">relative convenience and ease of administration.</td></tr></table><div style="clear: both"></div>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We are subject to various federal and state laws related to RAPIVAB and other products under development and, </b></i><i><b>if we or our partners do not comply with these regulations, we could face substantial penalties.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our or our partners&#146; activities related to RAPIVAB, or any of our other products under development and following their regulatory approval, are subject to regulatory and law enforcement authorities in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. In the case of our collaboration with SUL, although SUL is responsible for RAPIVAB marketing and commercialization efforts, we continue to carry certain risks associated with RAPIVAB because we hold the RAPIVAB NDA. For example, we are responsible for reporting adverse drug experiences, we have responsibility for certain post-approval studies, we may have responsibilities and costs related to a recall or withdrawal of RAPIVAB from sale, we may incur liability associated with RAPIVAB manufacturing contracted by us or in support of any of our partners, we are required to </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-16</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">maintain records and provide data and reports to regulatory agencies related to RAPIVAB (e.g. risk evaluation and mitigation strategies, track and trace requirements, adverse events), and we may incur certain promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial condition.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we are subject to the federal physician sunshine act and certain similar physician payment and drug pricing transparency legislation in various states. We are also subject to various federal and state laws pertaining to health care &#147;fraud and abuse,&#148; including both federal and state anti-kickback and false claims laws. These laws regulate our or our partners&#146; operations, sales and marketing practices, price reporting, and relationships with physicians and other customers and third-party payors. Anti-kickback laws generally prohibit a manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third party payors (including Medicare and Medicaid) claims for reimbursement or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. The sunshine provisions apply to manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government certain payments made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as, ownership and investment interests held by physicians (as defined above) and their immediate family members. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Although we seek to comply with these statutes, it is possible that our practices, or those of our partners, might be challenged under health care fraud and abuse, anti-kickback, false claims or similar laws. Violations of the physician sunshine act and similar state legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to certain regulatory authorities, including the FDA. Consequently, the FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator creates a conflict of interest or otherwise affects interpretation of the study. In the event of a conflict of interest with respect to a study, the integrity of the data generated at the applicable clinical trial site may be questioned or the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have a number of outstanding post-approval commitments to the FDA and European Medicines Agency (&#147;EMA&#148;) that we retain, despite our partnership with SUL, which we may not complete successfully or on time for any number of reasons, including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators or study subjects. For example, as a condition of the approval of RAPIVAB/ALPIVAB, we were required to complete pediatric patient trials and to submit the final results of these clinical trials to the FDA and EMA. We may be subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the approval of RAPIVAB/ALPIVAB and any other future product candidates may be subject to requirements for costly post-approval testing and surveillance to monitor its safety or efficacy.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Advertising and promotion are subject to stringent FDA rules and oversight and as the holder of the NDA we may be held responsible for any advertising and promotion conducted by our partner that is not in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent with the FDA approvals for approved products, and must be appropriately substantiated and fairly balanced with information on the safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed and as the NDA holder of RAPIVAB we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-17</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the research, manufacturing, distribution, sale and promotion of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. All of these activities are also potentially subject to federal and state healthcare false claims and fraud and abuse laws, as well as consumer protection and unfair competition laws. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If our operations with respect to RAPIVAB or our other products that are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. Moreover, achieving and sustaining compliance with all applicable federal and state fraud and abuse laws may be costly.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We and our partners may be subject to new legislation, regulatory proposals and healthcare payor initiatives that </b></i><i><b>may increase our costs of compliance and adversely affect our or our partners&#146; ability to market our products, </b></i><i><b>including RAPIVAB, obtain collaborators and raise capital.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Patient Protection and Affordable Care Act, or PPACA, made extensive changes to the delivery of health care in the U.S. The PPACA included numerous provisions that affect pharmaceutical companies, some of which became effective immediately and others of which have taken effect over the past several years. For example, the PPACA expanded health care coverage to the uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA also imposed substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels for health care items and services generally, including pharmaceuticals. It also required reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect that the current presidential administration and U.S. Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the PPACA. There is still significant uncertainty with respect to the impact that the current presidential administration and the U.S. Congress may have on the PPACA, if any, and any changes will likely take time to unfold. As such, we cannot predict what effect the PPACA or other healthcare reform initiatives that may be adopted in the future will have on our business.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care could result in decreased net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers are also required to report and disclose certain payments and transfers of value to, and investment interests held by, physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties for payments, transfers of value or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-18</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">face a material adverse effect on our business, financial condition, results of operations and growth prospects. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of operations.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Adequate coverage and reimbursement in the U.S. and other markets is critical to the commercial success of RAPIVAB or any other product that we might bring to market. Recently in the U.S. there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Individual states in the United States have been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. Third-party payors are increasingly challenging the prices charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many third-party payors negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the third-party payor&#146;s patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial condition and results of operations.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>There are risks related to the potential government use or sale of peramivir (RAPIVAB).</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">United States Government use or sale of RAPIVAB in emergency situations, or otherwise, may result in the use of RAPIVAB outside of its approved use. To the extent that RAPIVAB is used as a treatment for influenza by the U.S. Government or peramivir by any other government entity, there can be no assurance that it will prove to be generally safe, well-tolerated and effective. Such government use of RAPIVAB/peramivir may create certain liabilities for us or our partners in the case of government use outside of the U.S. There is no assurance that we or our manufacturers will be able to fully meet the demand for peramivir in the event of additional orders. Further, we may not achieve a favorable price for additional orders of RAPIVAB in the U.S. or peramivir in any other country. Our competitors may develop products that could compete with or replace peramivir. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully enforce our intellectual property rights.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There is no assurance that the non-U.S. partnerships that we have entered into for peramivir will result in any order for peramivir in those countries. There is no assurance that peramivir will be approved for any use or will achieve market approval in additional countries. In the event that any emergency use or market approval is granted, there is no assurance that any government order or commercialization of peramivir in any countries will be substantial or will be profitable to us. In addition, the sale of peramivir, emergency use or other use of peramivir in any country may create certain liabilities for us and our partners.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we or our partners do not obtain and maintain governmental approvals for our product candidates under </b></i><i><b>development, we or our partners will not be able to sell these potential products, which would significantly harm </b></i><i><b>our business because we will receive no revenue.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We or our partners must obtain regulatory approval before marketing or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. If the FDA delays regulatory approval of our product </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-19</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">candidates, our management&#146;s credibility, our value and our operating results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated uses for a product candidate and/or may require post-approval studies. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA regulates, among other things, the record keeping and storage of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products, whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements are wide ranging and govern, among other things:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">adverse drug experience reporting regulations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">product promotion;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">product manufacturing, including good manufacturing practice requirements; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">product changes or modifications.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our failure to comply with existing or future regulatory requirements, or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Royalties and milestone payments from Shionogi under our license agreement with Shionogi (the &#147;Shionogi </b></i><i><b>Agreement&#148;) will be required to be used by Royalty Sub to service its obligations under its PhaRMA Notes, and </b></i><i><b>generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations under </b></i><i><b>the PhaRMA Notes.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0 million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar Currency Hedge Agreement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest in Royalty Sub. Payments from Shionogi to us on non-governmental sales under the Shionogi Agreement will generally not be available to us for other purposes until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated to Royalty Sub&#146;s debt service and not available to us for product development or other purposes. As of September 1, 2014, the payments from Shionogi were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an event of default with respect to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs and we might otherwise be adversely affected.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Because an event of default has occurred under the PhaRMA Notes, the holders of the PhaRMA Notes may be </b></i><i><b>able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and </b></i><i><b>our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments that </b></i><i><b>might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely </b></i><i><b>affected.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Royalty Sub&#146;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks. Royalty Sub&#146;s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns, product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-20</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs and we might otherwise be adversely affected.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may be required to pay premiums under the Currency Hedge Agreement entered into by us in connection with </b></i><i><b>the issuance of the PhaRMA Notes. In addition, because our potential obligations under the foreign currency </b></i><i><b>hedge are marked to market, we may experience additional quarterly volatility in our operating results and cash </b></i><i><b>flows attributable to the Currency Hedge Agreement. </b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In connection with the issuance by Royalty Sub of the PhaRMA Notes, we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the amount of $2.0 million in May 2020. Such payment will be required if, in May 2020, the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less. We will be required to mark to market our potential obligations under the currency hedge and post cash collateral, which may cause us to experience additional quarterly volatility in our operating results and cash flows as a result. Additionally, we may be required to pay significant premiums or a termination fee under the foreign currency hedge agreement entered into by us in connection with the issuance of the PhaRMA Notes. We are required to maintain a foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our Senior Credit Facility contains restrictions that limit our flexibility in operating our business. We may be </b></i><i><b>required to make a prepayment or repay the outstanding indebtedness earlier than we expect if a prepayment event </b></i><i><b>or an event of default occurs, including a material adverse change with respect to us, which could have a material </b></i><i><b>adverse effect on our business.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Senior Credit Facility contains various covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">convey, sell, lease, license, transfer or otherwise dispose of certain parts of our business or property;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">change the nature of our business;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">liquidate or dissolve;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">enter into certain change in control or acquisition transactions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">incur or assume certain debt, including accessing additional tranches of debt under the Senior Credit Facility;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">grant certain types of liens on our assets;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">modify, liquidate or transfer assets in certain collateral accounts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">pay dividends or make certain distributions to our stockholders;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">make certain investments;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">enter into material transactions with affiliates; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">modify existing debt or collaboration arrangements.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The restrictive covenants contained in the Senior Credit Facility could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lender&#146;s permission or without repaying all Senior Credit Facility obligations.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A breach of any of these covenants could result in an event of default under the Senior Credit Facility. An event of default will also occur if, among other things, a material adverse change in our business, operations or condition occurs, which could potentially include negative results in clinical trials, or a material impairment of the prospect of our repayment of any portion of the amounts we owe under the Senior Credit Facility occurs. In the case of a continuing event of default under the agreement, the lender could elect to declare all amounts outstanding to be immediately due and payable, proceed against the collateral in which we granted to the lender a security interest under the Senior Credit Facility, or otherwise exercise the rights of a secured creditor. Amounts outstanding under the Senior Credit Facility are secured by substantially all of our assets and those of our subsidiaries, excluding certain specified assets but including proceeds from those assets.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-21</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the </b></i><i><b>value of those rights would diminish.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our success will depend in part on our ability and the abilities of our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#147;USPTO&#148;), the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions. The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We also rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our ability to receive patent protection or protect our proprietary information may be imperiled. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may be involved in legal proceedings to protect or enforce our patents, the patents of our partners or our other </b></i><i><b>intellectual property rights, which could be expensive, time consuming and unsuccessful.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any legal proceeding could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#146; patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors, we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-22</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we or our partners are unable or fail to adequately initiate, protect, defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions. We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed certain trademark and trade name applications worldwide. We cannot assure you as to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the degree and range of protection any patents will afford against competitors with similar products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">if and when patents will issue;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the USPTO or other foreign patent office upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">obtain licenses or redesign our products or processes to avoid infringement;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">stop using the subject matter claimed in those patents; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">pay damages.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may initiate, or others may bring against us, litigation or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any such proceeding may be substantial whether or not we are successful.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our success is also dependent upon the skills, knowledge and experience, none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates and any such events would significantly impair the value of such product candidates.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our actual or perceived failure to comply with European governmental regulations and other legal obligations </b></i><i><b>related to privacy, data protection and information security could harm our business.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">European Union (&#147;EU&#148;) member states, Switzerland and other countries have adopted data protection laws and regulations, which impose significant compliance obligations. For example, the General Data Protection Regulation (&#147;GDPR&#148;) imposes strict requirements on controllers and processors of personal data, including special protections for &#147;special category data,&#148; which includes health, biometric and genetic information of data subjects located in the EU. Further, GDPR provides a broad right for EU member states to create supplemental national laws, for example relating to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase and harm our business and financial condition. GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedies in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules on the transfer of personal data out of the EU to the United States or other regions that have not been deemed to offer &#147;adequate&#148; privacy protections.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-23</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU member states, which may deviate slightly from the GDPR, may result in significant fines of up to 4% of global revenues, or &#8364;20,000,000, whichever is greater, and in addition to such fines, our failure to comply with the requirements of GDPR may subject us to litigation and/or adverse publicity, which could have material adverse effect on our reputation and business. As a result of the implementation of the GDPR, we are required to put in place additional mechanisms to ensure compliance with the new data protection rules. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout the EU, imposes additional obligations on us when we are contracting with service providers and requires us to adopt appropriate privacy governance including policies, procedures, training and data audit.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are subject to the supervision of local data protection authorities in those jurisdictions where we undertake clinical trials. We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU individuals on our behalf. With each such provider we are required to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct diligence to ensure that they have sufficient technical and organizational security measures in place.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are also subject to evolving European privacy laws on electronic marketing and cookies. The EU is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation that will be directly implemented in the laws of each European member state. While the e-Privacy Regulation was originally intended to be adopted on May 25, 2018, it is still going through the European legislative process and commentators now expect it to be adopted during the middle or second half of 2020.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The United Kingdom&#146;s decision to withdraw from the EU could result in increased regulatory and legal </b></i><i><b>complexity, which may make it more difficult for us to do business in Europe and impose additional challenges </b></i><i><b>in securing regulatory approval of our product candidates in Europe.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Negotiations for the United Kingdom&#146;s exit from the EU, or Brexit, have caused political and economic uncertainty, including in the regulatory framework applicable to our operations and product candidates, and this uncertainty may persist for years. Brexit could, among other outcomes, disrupt the free movement of goods, services and people between the United Kingdom and the EU, and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in Europe. For instance, preparations for Brexit have resulted in the decision to move the EMA from the United Kingdom to the Netherlands. This transition may cause disruption or delays in granting clinical trial authorization or opinions for marketing authorization, disruption of importation and export of active substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the EU and/or the United Kingdom. It is possible that there will be increased regulatory complexities, which can disrupt the timing of our clinical trials and regulatory approvals. In addition, changes in, and legal uncertainty with regard to, national and international laws and regulations may present difficulties for our clinical and regulatory strategy. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the EU and restrict our ability to generate revenues and achieve and sustain profitability.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, as a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership with the EU. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the EU would have and how such withdrawal would affect us, and the full extent to which our business could be adversely affected.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We are subject to legal proceedings, which could result in losses or unexpected expenditure of time and resources.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From time to time, we may be involved in disputes, called upon to initiate legal proceedings or to defend ourselves in such legal proceedings relating to our business. Due to the inherent uncertainties in legal proceedings, we cannot accurately predict the ultimate outcome of any such proceedings. An unfavorable outcome in any such proceedings </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-24</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">could have an adverse impact on our business, financial condition and results of operations. If our stock price is volatile, we may become involved in securities class action lawsuits in the future. Any current or future dispute resolution or legal proceeding, including without limitation the ongoing arbitration proceeding between us and SUL, regardless of the merits of any such proceeding, could result in substantial costs and a diversion of management&#146;s attention and resources that are needed to successfully run our business.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We face an inherent risk of liability in the event that the use or misuse of our products results in personal injury </b></i><i><b>or death and our product liability insurance coverage may be insufficient.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the use or misuse of peramivir, forodesine or any other regulatory body-approved products we or a partner may sell in the future harms people, we may be subject to costly and damaging product liability claims brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product candidates and, therefore, the amount of insurance coverage we currently have may not be adequate to cover all liabilities or defense costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us of our product candidates. We have product liability insurance covering our clinical trials. Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">withdrawal of clinical trial volunteers or patients;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">damage to our reputation and the reputation of our products, resulting in lower sales;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulatory investigations that could require costly recalls or product modifications;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">litigation costs; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the diversion of management&#8217;s attention from managing our business.</td></tr></table><div style="clear: both"></div>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Insurance coverage is increasingly more costly and difficult to obtain or maintain.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">While we currently have insurance for our business, property, directors and officers, and our products, insurance is increasingly more costly and narrower in scope, and we may be required to assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain or maintain insurance coverage at reasonable costs or at all.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If our facility incurs damage or power is lost for a significant length of time, our business will suffer.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We store clinical and stability samples at our facility that could be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant delays in our drug development process.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-25</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we store most of our preclinical and clinical data at our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug development process and any system failure could harm our business and operations.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>A significant disruption in our information technology systems or a cyber-security breach could adversely affect </b></i><i><b>our business.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are increasingly dependent on information technology systems to operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information technology systems could negatively impact operations. If our systems are damaged, fail to function properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and any such events could adversely affect our business.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development </b></i><i><b>of our product candidates and commercialization of our products and the related expansion of our business will </b></i><i><b>be delayed or stopped.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are highly dependent upon our senior management and scientific team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm our business because we rely upon these personnel for many critical functions of our business.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If because of our use of hazardous materials, we violate any environmental controls or regulations that apply to </b></i><i><b>such materials, we may incur substantial costs and expenses in our remediation efforts.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Relating </b><b>t</b><b>o </b><b>t</b><b>his Offering, </b><b>t</b><b>he Pre-Funded Warrants </b><b>a</b><b>nd </b><b>o</b><b>ur Common Stock</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>There is no public market for the pre-funded warrants being offered in this offering.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There is no established public trading market for the pre-funded warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list these warrants on any securities exchange or nationally recognized trading system, including The Nasdaq Global Select Market. Without an active market, the liquidity of these warrants will be limited.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Holders of pre-funded warrants purchased in this offering will have no rights as common stockholders until such </b></i><i><b>holders exercise their warrants and acquire our common stock.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Until holders of the pre-funded warrants acquire shares of our common stock upon exercise of such warrants, the holders will have no rights with respect to the shares of our common stock underlying such warrants. Upon exercise of the warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-26</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Management will have broad discretion in the application of the net proceeds, including any of the purposes described in &#147;Use of Proceeds.&#148; The failure by our management to apply these funds effectively could have a material adverse effect on our business.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence </b></i><i><b>significant corporate decisions, which may conflict with the interest of other stockholders.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Several of our stockholders own greater than 5% of our outstanding common stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate actions.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an </b></i><i><b>investment in our common stock to decline significantly. </b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently, and these fluctuations are often not related to our financial results. For the twelve months ended September 30, 2019, the 52-week range of the market price of our stock was from $2.49 to $9.95 per share. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">announcements of technological innovations or new products by us or our competitors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">developments or disputes concerning patents or proprietary rights;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">additional dilution through sales of our common stock or other derivative securities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">status of new or existing licensing or collaborative agreements and government contracts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">announcements relating to the status of our programs;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">developments and announcements regarding new and virulent strains of influenza;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we or our partners achieving or failing to achieve development milestones;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">publicity regarding certain public health concerns for which we are or may be developing treatments;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulatory developments in both the United States and foreign countries;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">public concern as to the safety of pharmaceutical products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">actual or anticipated fluctuations in our operating results;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changes in financial estimates or recommendations by securities analysts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">changes in the structure of healthcare payment systems, including developments in price control legislation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">additions or departures of key personnel or members of our board of directors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">economic and other external factors or other disasters or crises; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">period-to-period fluctuations in our financial results.</td></tr></table><div style="clear: both"></div>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Future sales and issuances of securities may dilute the ownership interests of our current stockholders and cause </b></i><i><b>our stock price to decline.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Future sales of our common stock by current stockholders into the public market could cause the market price of our stock to fall. As of November 19, 2019, there were 154,059,115 shares of our common stock outstanding. We may </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-27</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition. We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms to be determined at the time of sale.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of November 19, 2019, there were a total of 19,147,628 stock options outstanding, 4,064,450 shares available for issuance under our Amended and Restated Stock Incentive Plan, 333,276 shares available for issuance under our Inducement Equity Incentive Plan, and 119,194 shares available for issuance under our Employee Stock Purchase Plan. In addition, we could also make equity grants outside of our Stock Incentive Plan or Inducement Equity Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If some or all of such shares are sold or otherwise issued into the public market over a short period of time, our current stockholders&#146; ownership interests may be diluted and the value of all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices. Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable, or at all.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In March 2017, we entered into a Registration Rights Agreement with entities affiliated with Baker Bros. Advisors LP (the &#147;Baker Entities&#148;) to provide that, if requested, we will register the shares of our common stock beneficially owned by the Baker Entities for resale under the Securities Act. Our registration obligations pursuant to the Registration Rights Agreement cover all shares then held or thereafter acquired by the Baker Entities, including the shares of our common stock issuable upon exercise of the pre-funded warrants, for up to ten years, and include our obligation to facilitate certain underwritten public offerings of our common stock by the Baker Entities in the future. On May 10, 2017, we filed a registration statement on Form S-3 with respect to 11,710,951 shares of common stock held by the Baker Entities. If the Baker Entities, by exercising their underwriting rights or otherwise, sell a large number of our shares, or the market perceives that the Baker Entities intend to sell a large number of our shares, this could adversely affect the market price of our common stock. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you </b></i><i><b>do not agree.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our board of directors has the authority to issue up to 4,800,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties to acquire a majority of our outstanding voting stock.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, our certificate of incorporation provides for staggered terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have never paid cash dividends on our stock. We currently intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash dividends on our common stock in the foreseeable future.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-28</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 104-use -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sUOP"></a><b>USE OF PROCEEDS</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We estimate that we will receive net proceeds of approximately $19.8 million from the sale of pre-funded warrants to purchase 11,764,706 shares of our common stock, after deducting estimated offering expenses payable by us and excluding any proceeds we may receive upon the exercise of the pre-funded warrants. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The net proceeds we expect to receive from the sale of any securities offered hereunder will be added to our general funds and used for general corporate purposes, which may include, but are not limited to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">worldwide development, manufacturing, regulatory and commercial activities for the prophylactic BCX7353 program, primarily focusing on the U.S., EU and Japan;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">development of the BCX9930 program;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">development of the BCX9250 program;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">post-approval commitments for RAPIVABTM/ALPIVABTM;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">funding clinical development of pipeline assets; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">capital expenditures and other general corporate expenses.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The amount and timing of these expenditures will depend on a number of factors, including the progress of our research and development efforts and amounts received under our existing and any future government contracts and collaboration arrangements, as well as the amount of cash used in our operations. Accordingly, our management will have broad discretion in the application of these proceeds, and investors will be relying on the judgment of our management with regard to the use of these proceeds. Pending application of the net proceeds as described above, we intend to invest the net proceeds in investment grade interest bearing instruments.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-29</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sDIL"></a><b>DILUTION</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of September 30, 2019, our net tangible book value, as adjusted for the issuance of 43,620,690 shares of common stock in the Common Stock Offering on November 18, 2019, was approximately $17.8 million, or approximately $0.12 per share of common stock. Net tangible book value per share represents the amount of our total assets, excluding deferred collaboration expenses, less total liabilities, excluding deferred collaboration revenues, divided by the 154,059,115 shares of our common stock outstanding as of September 30, 2019, as adjusted for the issuance of 43,620,690 shares of common stock in the Common Stock Offering on November 18, 2019.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Investors participating in this offering will incur immediate, substantial dilution. After giving effect to our receipt of approximately $19.9 million of estimated net proceeds (after deducting estimated offering expenses payable by us) from our issuance of the 11,764,706 shares of common stock in this offering (assuming exercise of all of the pre-funded warrants), our as adjusted net tangible book value as of September 30, 2019 would have been $37.7 million, or $0.23 per share. This amount represents an immediate increase in net tangible book value of $0.11 per share of our common stock to existing stockholders and an immediate dilution in net tangible book value of $1.47 per share of our common stock to investors participating in this offering.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table illustrates this dilution on a per share basis:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-top: 1pt solid #000000; border-bottom: 1pt solid #000000; border-collapse: collapse; ">
									<tr style="background-color: #cceeff;">
	<td colspan="1" width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.50px; ">Public offering price per share</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="5%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1.70</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.50px; ">As adjusted net tangible book value per share as of September 30, 2019</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 0.12</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.50px; ">Increase in net tangible book value per share attributable to investors participating in this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 0.11</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.50px; ">As adjusted net tangible book value per share as of September 30, 2019 after giving effect to this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="5%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 0.23</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.50px; ">Dilution in net tangible book value per share to investors participating in this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="5%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1.47</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ccedff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; background-color: #ffffff; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The above discussion and table are based on 154,059,115 shares of our common stock outstanding as of September 30, 2019, as adjusted for the issuance of 43,620,690 shares of common stock in the Common Stock Offering on November 18, 2019, and excludes:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">17,980,904 shares of common stock issuable upon the exercise of stock options outstanding under our Stock Incentive Plan as of September 30, 2019, at a weighted average exercise price of $6.53 per share;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">999,224 shares of common stock issuable upon the exercise of stock options outstanding under our Inducement Equity Incentive Plan as of September 30, 2019, at a weighted average exercise price of $4.03 per share; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">4,064,450 additional shares of common stock reserved for issuance under our Stock Incentive Plan, 500,776 additional shares of common stock reserved for issuance under our Inducement Equity Incentive Plan, and 119,194 additional shares of common stock reserved for issuance under our Employee Stock Purchase Plan as of September 30, 2019.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To the extent that outstanding options have been or may be exercised or other shares issued, there may be further dilution to investors. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital by issuing equity securities or convertible debt, your ownership may be further diluted.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-30</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sDOS"></a><b>DESCRIPTION OF </b><b>PRE-FUNDED WARRANTS</b><b> </b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In this offering, we are offering 11,764,706 pre-funded warrants to purchase shares of our common stock. The following description is subject in all respects to the provisions contained in the form of pre-funded warrant.You should review a copy of the form of pre-funded warrant, which is attached as an exhibit to our Current Report on Form 8-K being filed with the Securities and Exchange Commission in connection with this offering, for a complete description of the terms and conditions of the pre-funded warrants. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The pre-funded warrants will be issued as individual warrant agreements to the holders. The pre-funded warrants are exercisable at any time after their original issuance at an exercise price of $0.01 per share. The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. As an alternative to payment in immediately available funds, the holder may, in its sole discretion, elect to exercise the pre-funded warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. No fractional shares of common stock will be issued in connection with the exercise of a pre-funded warrant. In lieu of issuing fractional shares, we will pay the holder an amount in cash equal to the fair market value of any fractional share, calculated based on the trading price of our common stock. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The exercise price per whole share of our common stock purchasable upon the exercise of the pre-funded warrants is $0.01 per share of common stock. The exercise price of the pre-funded warrants is subject to adjustment from time to time in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions for no consideration of assets, including cash, stock or other property, to all of our stockholders. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A holder will not have the right to exercise any portion of the pre-funded warrant if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise. However, any holder may increase or decrease such ownership percentage limit to any other percentage not in excess of 19.99% upon at least 61 days&#146; prior notice from the holder to us. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not plan on applying to list the pre-funded warrants on the Nasdaq Global Select Market or any other national securities exchange or automated quotation system. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to applicable laws, the pre-funded warrants may be offered for sale, sold, transferred or assigned without our consent. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the event of a fundamental transaction, as defined in the pre-funded warrants and generally including, without limitation, any reclassification of our common stock into other securities, cash or property, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition by any person or group, whether in a tender offer, exchange offer, stock purchase agreement, or other business combination, of more than 50% of the voting power of our capital stock, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the same amount and kind of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Except by virtue of such holder&#146;s ownership of shares of our common stock, the holder of a pre-funded warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the pre-funded warrant. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-31</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sPOD"></a><b>PLAN OF DISTRIBUTION </b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are offering 11,764,706 pre-funded warrants under this prospectus supplement and the accompanying prospectus directly to investors at a price of approximately $1.69 per warrant. Each pre-funded warrant will have an exercise price of $0.01 per share. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into a Securities Purchase Agreement (the &#147;Purchase Agreement&#148;) with the investors named therein for the full amount of the offering. The Purchase Agreement is included as an exhibit to our Current Report on Form 8-K that we will file with the SEC in connection with the consummation of this offering. See &#147;Where You Can Find Additional Information&#148;. Our obligation to issue and sell the pre-funded warrants is subject to the conditions set forth in the Purchase Agreement. The investors have agreed, for a period of seven calendar days after the date the pre-funded warrants are issued, not to (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of the our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, the pre-funded warrants), or publicly disclose the intention to undertake any of the foregoing, (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of common stock or such other securities, in cash or otherwise, or (iii) make any demand for or exercise any right with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock. The investors agreed to the restrictions described in the previous sentence as a condition to the waiver by the underwriters of a 60-day &#8220;clear market provision&#8221; described in the Underwriting Agreement entered into by the Company in connection with the Common Stock Offering, which would have prohibited the Company from entering into the Purchase Agreement. We have agreed to indemnify the investors in this offering against certain liabilities as set forth in the Purchase Agreement. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We currently anticipate that the sale of the securities offered by this prospectus supplement and the accompanying base prospectus will be completed on or about November 21, 2019, subject to customary closing conditions. We estimate the total offering expenses of this offering that will be payable by us will be approximately $100,000, which includes legal and printing costs and various other fees. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The pre-funded warrants are being offered directly to the investors without a placement agent, underwriter, broker or dealer. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-32</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sLEGAL"></a><b>LEGAL MATTERS</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Gibson, Dunn &amp; Crutcher LLP will pass upon the validity of the securities offered hereby.</p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sEXP"></a><b>EXPERTS</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018, and the effectiveness of our internal control over financial reporting as of December 31, 2018, as set forth in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements and our management&#146;s assessment of the effectiveness of internal control over financial reporting as of December 31, 2018 are incorporated by reference in reliance on Ernst &amp; Young LLP&#146;s reports, given on their authority as experts in accounting and auditing.</p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sWYCFMI"></a><b>WHERE YOU CAN FIND MORE INFORMATION</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and other information. We make available on or through our website, http://www.biocryst.com, free of charge, copies of these filings as soon as reasonably practicable after we electronically file them with or furnish them to the SEC. The information on our website is not incorporated by reference into this prospectus supplement. You can also request copies of such documents by contacting our Investor Relations Department at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703 or sending an email to investorrelations@biocryst.com.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The SEC also maintains a website that contains reports, proxy statements and other information about issuers, like BioCryst, that file electronically with the SEC. The address of that site is http://www.sec.gov. Unless specifically listed below under &#147;Incorporation of Certain Documents by Reference&#148; the information contained on the SEC website is not incorporated by reference into this prospectus supplement.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have filed with the SEC a registration statement on Form S-3 that registers the securities we are offering. The registration statement, including the attached exhibits and schedules, contains additional relevant information about us and our securities. The rules and regulations of the SEC allow us to omit certain information included in the registration statement from this prospectus supplement.</p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="sINC"></a><b>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus supplement. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus supplement, except for any information that is superseded by information that is included directly in this document.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus supplement includes by reference the documents listed below that we have previously filed with the SEC and that are not included in or delivered with this document. They contain important information about us and our financial condition.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">Our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319001727/f10k_031219p.htm">March 14, 2019</a> (including the sections of our proxy statement relating to our May 29, 2019 annual meeting of stockholders that are incorporated by reference therein);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2019, June 30, 2019 and September 30, 2019, filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319003220/f10q_050919p.htm">May 9, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319005326/f10q_080819p.htm">August 8, 2019</a> and <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319007384/f10q_110819p.htm">November 8, 2019</a>, respectively;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">Our Current Reports on Form 8-K filed with the SEC on January 2, 2019, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319000126/f8k_010419.htm">January 4, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319000749/f8k_020619.htm">February 6, 2019</a> (Items 1.01 and 2.03 only), <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319003529/f8k_052119.htm">May 21, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319003812/f8k_053119.htm">June 4, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319004220/f8k_062719.htm">June 27, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319004257/f8k_070119.htm">July 1, 2019</a> (Items 5.02 only), <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319005941/f8k_091619.htm">September 16, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319006063/f8k_092319.htm">September 23, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319006137/f8k_092519.htm">September 26, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319006859/f8k_102819.htm">October 28, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319007064/f8k_110119.htm">November 1, 2019</a>; <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319007155/f8k_110519.htm">November 5, 2019</a>; <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319007363/f8k_110819.htm">November 8, 2019</a> and <a href="http://www.sec.gov/Archives/edgar/data/882796/000114036119020752/nc10006218x1_8k.htm">November 18, 2019</a>; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">The description of our common stock which is contained in our Registration Statement on Form 8-A (File No. 000-23186) filed with the SEC on January 8, 1994, including any amendment or reports filed for the purpose of updating such description.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-33</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All documents filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement and prior to the termination of this offering shall be deemed to be incorporated by reference herein and to be a part of this prospectus supplement from the date of filing of such documents. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed &#147;filed&#148; with the SEC, including any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K and exhibits filed on such form that are related to such items. Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">You can obtain any of the documents incorporated by reference in this prospectus supplement from us without charge, excluding any exhibits to those documents unless the exhibit is specifically incorporated by reference as an exhibit to this prospectus supplement, by requesting them in writing or by telephone from us at the following address and telephone number:</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Investor Relations<br>BioCryst Pharmaceuticals, Inc.<br>4505 Emperor Blvd., Suite 200<br>Durham, North Carolina 27703<br>(919) 859-7910</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or any free writing prospectus prepared by us or on our behalf. We take no responsibility for, or can provide no assurances as to the reliability of, any information other than the information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or any free writing prospectus prepared by us or on our behalf. If you are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this document are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this document does not extend to you.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">S-34</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 200-letter -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>PROSPECTUS</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; "><img src="logo_biocryst2a.jpg" alt="" style="height: 114.40px; width: 281.60px; scale: ">&#8201;<br></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 18.67px; line-height: 19.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; "><b>$200,000,000<br></b><b>Common Stock<br></b><b>Preferred Stock<br></b><b>Depositary Shares<br></b><b>Stock Purchase Contracts<br></b><b>Warrants<br></b><b>Units</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; ">By this prospectus, we may from time to time offer securities to the public. We will provide specific terms of these securities in supplements to this prospectus. You should read this prospectus, the applicable prospectus supplement, and the information incorporated by reference in this prospectus and the applicable prospectus supplement carefully before you invest.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our common stock, par value $0.01 per share, trades on the NASDAQ Global Select Market under the symbol &#147;BCRX.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have not authorized anyone else to make additional representations or to provide you with information other than information provided or incorporated by reference in this prospectus or any prospectus supplement. We take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you or representations that others may make. We are not making or soliciting an offer of any securities other than the securities described in this prospectus and any prospectus supplement. We are not making or soliciting an offer of these securities in any state or jurisdiction where the offer is not permitted or in any circumstances in which such offer or solicitation is unlawful. You should not assume that the information contained or incorporated by reference in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of those documents.</p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Investing in these securities involves a high degree of risk. See &#147;Risk Factors&#148; on page </b><b><a href="#pRF">2</a></b><b> of this </b><b>prospectus, in the applicable prospectus supplement we will deliver with this prospectus and in the </b><b>documents incorporated herein and therein by reference.</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; ">The securities may be sold by us to or through underwriters or dealers, directly to purchasers or through agents designated from time to time, or through a combination of these methods. For additional information on the methods of sale, you should refer to the section entitled &#147;Plan of Distribution&#148; in this prospectus. If any underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable discounts or commissions and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. This prospectus may not be used to sell any securities unless accompanied by a prospectus supplement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or </b><b>disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any </b><b>representation to the contrary is a criminal offense.</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; ">The date of this prospectus is December 12, 2017. </p>
			<div style="clear: both;"></div></div>





<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 201-toc -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>TABLE OF CONTENTS</b></p>
				<a name="TOC"></a><table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; ">&#160;</div></td>
	<td colspan="3" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.52px; padding-right: 0px; "><b>Page</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pATP">ABOUT THIS PROSPECTUS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pATP">i</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pPS">PROSPECTUS SUMMARY</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pPS">1</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pRF">RISK FACTORS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pRF">2</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pIRS">INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pIRS">3</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pUOP">USE OF PROCEEDS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pUOP">5</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pDPD">DESCRIPTION OF COMMON STOCK, PREFERRED STOCK AND DEPOSITARY SHARES</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pDPD">6</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pDPC">DESCRIPTION OF STOCK PURCHASE CONTRACTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pDPC">9</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pDOW">DESCRIPTION OF WARRANTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pDOW">10</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pDOU">DESCRIPTION OF UNITS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pDOU">11</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pPOD">PLAN OF DISTRIBUTION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pPOD">12</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pLM">LEGAL MATTERS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pLM">15</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pEXP">EXPERTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pEXP">15</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pWFI">WHERE YOU CAN FIND MORE INFORMATION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pWFI">16</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="95%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.52px; "><a href="#pICR">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="2%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#pICR">16</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pATP"></a><b>ABOUT THIS PROSPECTUS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148; registration or continuous offering process. Under this registration statement, we may sell any combination of the securities described in this prospectus from time to time, either separately or in units, in one or more offerings. Together, these offerings may total up to $200.0 million.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement containing specific information about the terms of that offering. That prospectus supplement may add, update or change information contained in this prospectus and will also include the following information:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the type and amount of securities that we propose to sell;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the public offering price of the securities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the names of any underwriters, agents or dealers through or to which the securities will be sold;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any compensation of those underwriters, agents or dealers;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">information about any securities exchanges or automated quotation systems on which the securities will be listed or traded;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any risk factors applicable to the securities that we propose to sell; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any other material information about the offering and sale of the securities.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If there is any inconsistency between the information in this prospectus and any prospectus supplement, you should rely on the information in the prospectus supplement. You should read both this prospectus and any prospectus supplement together with the additional information described under the heading &#147;Where You Can Find More Information.&#148; The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under this prospectus. The registration statement, including the exhibits, can be read at the SEC&#146;s website or at the SEC&#146;s offices referenced under the heading &#147;Where You Can Find More Information.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All references to &#147;Company,&#148; &#147;we,&#148; &#147;our,&#148; or &#147;us&#148; refer solely to BioCryst Pharmaceuticals, Inc. and not to the persons who manage us or sit on our Board of Directors. All trade names used in this prospectus are either our registered trademarks or trademarks of their respective holders.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">i</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 202-summary -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pPS"></a><b>PROSPECTUS SUMMARY</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This summary highlights information contained elsewhere or incorporated by reference into this prospectus. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities. You should read this entire prospectus carefully, including the section entitled &#147;Risk Factors&#148; and the documents that we incorporate by reference into this prospectus, before making an investment decision.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Business of BioCryst Pharmaceuticals, Inc.</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases in which significant unmet medical needs exist and that align with our capabilities and expertise. We integrate the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a Delaware corporation originally founded in 1986. Our principal executive offices are located at 4505 Emperor Blvd. Suite 200, Durham, North Carolina 27703, and our telephone number is (919) 859-1302. For more information about us, please visit our website at http://www.biocryst.com. The information on our web site is not incorporated by reference into this prospectus.</p>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">1</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 203-risk -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pRF"></a><b>RISK FACTORS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Investing in our securities involves risks. Our business is influenced by many factors that are difficult to predict and beyond our control and that involve uncertainties that may materially affect our business, results of operations, financial condition or cash flows, or the value of these securities. These risks and uncertainties are described in the risk factors section of the documents that are incorporated by reference in this prospectus. Any subsequent prospectus supplement may contain a discussion of additional risks applicable to an investment in us and the particular type of securities we are offering under such prospectus supplement. You should carefully consider all of the information contained in or incorporated by reference in this prospectus and in the applicable prospectus supplement before you invest in our securities.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">2</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 204-info -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pIRS"></a><b>INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus and any subsequent prospectus supplement, including the information we incorporate by reference, contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), which are subject to the &#147;safe harbor&#148; created in Section 21E. All statements other than statements of historical facts contained in this prospectus, any subsequent prospectus supplement and the information we incorporate by reference are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;believes,&#148; &#147;anticipates,&#148; &#147;expects,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. These forward-looking statements include, but are not limited to, statements about:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the preclinical development, clinical development, commercialization, or post-marketing studies of our product candidates and products, including our hereditary angioedema (&#147;HAE&#148;) program, peramivir, galidesivir, and early stage discovery programs;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the potential funding from our contracts with the Biomedical Advanced Research and Development Authority (the &#147;BARDA/HHS&#148;) and the National Institute of Allergy and Infectious Diseases (&#147;NIAID/HHS&#148;) for the development of galidesivir;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the potential for government stockpiling orders of peramivir, additional regulatory approvals of peramivir, or milestones, royalties or profit from sales of peramivir by us or our partners;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the potential use of peramivir as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to establish and maintain collaborations or out-license rights to our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">plans, programs, progress and potential success of our collaborations, including Seqirus UK Limited (&#147;SUL&#148;) for peramivir, Mundipharma International Holdings Limited (&#147;Mundipharma&#148;) for forodesine, and Shionogi &amp; Co., Ltd. (&#147;Shionogi&#148;) and Green Cross Corporation (&#147;Green Cross&#148;) for peramivir in their territories;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the ability of our wholly-owned subsidiary, JPR Royalty Sub LLC (&#147;Royalty Sub&#148;), to service its payment obligations in respect of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#147;PhaRMA Notes&#148;);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to operate our business without infringing the intellectual property rights of others;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">estimates of our expenses, revenues, capital requirements, annual cash utilization, and our needs for additional financing;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to continue as a going concern;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing or likelihood of regulatory filings or regulatory agreements, deferrals and approvals;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to raise additional capital to fund our operations or repay our recourse debt obligations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to comply with the covenants as set forth in the agreements governing our debt obligations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our financial performance; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">competitive companies, technologies and our industry.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#147;Risk Factors&#148; and elsewhere in this prospectus, any subsequent </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">3</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">prospectus supplement and the documents incorporated by reference. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Discussions containing these forward-looking statements are also contained in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; incorporated by reference from our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarters ended since our most recent Annual Report, and our Current Reports on Form 8-K, as well as any future amendments we make to those filings or future filings with the SEC.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">4</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pUOP"></a><b>USE OF PROCEEDS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Except as otherwise described in the applicable prospectus supplement, the net proceeds we expect to receive from the sale of any securities offered hereunder will be added to our general funds and used for general corporate purposes, which may include, but are not limited to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">funding development, manufacturing and regulatory activities for BCX7353;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">pre-launch commercial activities for BCX7353;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the advancement of development activities on other rare disease targets;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">funding development, manufacturing and regulatory activities for other second generation HAE compounds;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">post-approval commitments for RAPIVAB&#8482;;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">funding our research and development efforts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">capital expenditures; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">general working capital needs.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may also use a portion of the net proceeds to acquire or invest in businesses, assets, products and technologies that are complementary to our own, although we are not currently contemplating or negotiating any such acquisitions or investments.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The amount and timing of these expenditures will depend on a number of factors, including the progress of our research and development efforts and amounts received under our existing and any future government contracts and collaboration arrangements, as well as the amount of cash used in our operations. Accordingly, our management will have broad discretion in the application of these proceeds, and investors will be relying on the judgment of our management with regard to the use of these proceeds. Pending application of the net proceeds as described above, we intend to invest the net proceeds in investment grade interest bearing instruments.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">5</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 205-desc -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pDPD"></a><b>DESCRIPTION OF COMMON STOCK, PREFERRED STOCK AND DEPOSITARY SHARES</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following summary description of our capital stock summarizes general terms and provisions that apply to the capital stock. Because this is only a summary, it does not contain all of the information that may be important to you. This summary is subject to and qualified in its entirety by reference to our restated certificate of incorporation, as amended, by-laws, as amended, and the rights agreement, as amended, each of which are on file with the SEC. See &#147;Where You Can Find More Information.&#148;</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Authorized and Outstanding Capital Stock</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of preferred stock, par value $0.01 per share, of which 200,000 shares are designated Series B Junior Participating Preferred Stock with a par value of $0.001 per share. On November 6, 2017, there were 98,404,761 shares of common stock outstanding and no shares of preferred stock outstanding.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Common Stock</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Holders of our common stock are entitled to one vote per share on all matters submitted to a vote of stockholders and may not cumulate votes for the election of directors. Common stockholders have the right to receive dividends as and when declared by the Board of Directors from funds legally available therefor, subject to any preferential dividend rights of any preferred stock then outstanding. Upon our dissolution or liquidation, common stockholders are entitled to receive all assets legally available for distribution to stockholders, subject to any preferential rights of any preferred stock then outstanding. Holders of common stock have no preemptive rights and have no rights to convert their common stock into any other securities.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Preferred Stock</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Preferred stock may be issued from time to time in one or more series, each such series to have such terms as determined by our Board of Directors. Our Board of Directors has the authority to determine and fix such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation dividend rights, conversion rights, redemption privileges and liquidation preferences, without further vote or action by our stockholders. We will distribute a prospectus supplement with regard to each particular series of preferred stock that will describe the terms and provisions of that series of preferred stock. The rights of the holders of any preferred stock that may be issued may adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties to acquire a majority of our outstanding voting stock.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Anti-Takeover Provisions</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our certificate of incorporation provides for staggered terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors and prevents our stockholders from acting by written consent or from calling special meetings of stockholders. Our certificate also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Depositary Shares</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may, at our option, elect to offer fractional shares of preferred stock, rather than full shares of preferred stock. If we exercise this option, we will issue to the public receipts for depositary shares, and each of these depositary shares will represent a fraction, to be set forth in the applicable prospectus supplement, of a share of a particular series of preferred stock.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The shares of any series of preferred stock underlying the depositary shares will be deposited under a deposit agreement between us and a bank or trust company selected by us. The depositary will have its principal office in the United States and a combined capital and surplus of at least $50,000,000. Subject to the terms of the deposit agreement, each owner of a depositary share will be entitled, in proportion to the applicable fraction of a share of preferred stock underlying the depositary share, to all the rights and preferences of the preferred stock underlying that depositary share. Those rights may include dividend, voting, redemption, conversion and liquidation rights.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">6</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The depositary shares will be evidenced by depositary receipts issued under a deposit agreement. Depositary receipts will be distributed to those persons purchasing the fractional shares of preferred stock underlying the depositary shares, in accordance with the terms of the offering. The following description of the material terms of the deposit agreement, the depositary shares and the depositary receipts is only a summary and you should refer to the forms of the deposit agreement and depositary receipts that will be filed with the SEC in connection with the offering of the specific depositary shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pending the preparation of definitive engraved depositary receipts, the depositary, upon our written order, may issue temporary depositary receipts substantially identical to the definitive depositary receipts but not in definitive form. These temporary depositary receipts would entitle their holders to all the rights of definitive depositary receipts. Temporary depositary receipts would be exchangeable for definitive depositary receipts at our expense.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Dividends and Other Distributions</i>. The depositary will distribute all cash dividends or other cash distributions received with respect to the underlying stock to the record holders of depositary shares in proportion to the number of depositary shares owned by those holders.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If there were a distribution other than in cash, the depositary would distribute property received by it to the record holders of depositary shares that are entitled to receive the distribution, unless the depositary determines that it is not feasible to make the distribution. If this occurs, the depositary, with our approval, would sell the property and distribute the net proceeds from the sale to the applicable holders.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Withdrawal of Underlying Preferred Stock</i>. Unless we provide otherwise in a prospectus supplement, holders may surrender depositary receipts at the principal office of the depositary and, upon payment of any unpaid amount due to the depositary, would be entitled to receive the number of whole shares of underlying preferred stock and all money and other property represented by the related depositary shares. We will not issue any partial shares of preferred stock. If the holder delivers depositary receipts evidencing a number of depositary shares that represent more than a whole number of shares of preferred stock, the depositary will issue a new depositary receipt evidencing the excess number of depositary shares to that holder.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Redemption of Depositary Shares</i>. If a series of preferred stock represented by depositary shares were subject to redemption, the depositary shares would be redeemed from the proceeds received by the depositary resulting from the redemption, in whole or in part, of that series of underlying stock held by the depositary. The redemption price per depositary share would be equal to the applicable fraction of the redemption price per share payable with respect to that series of underlying stock. Whenever we redeem shares of underlying stock that are held by the depositary, the depositary will redeem, as of the same redemption date, the number of depositary shares representing the shares of underlying stock so redeemed. If fewer than all the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected by lot or proportionately, as may be determined by the depositary.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Voting</i>. Upon receipt of notice of any meeting at which the holders of the underlying stock are entitled to vote, the depositary will mail the information contained in the notice to the record holders of the depositary shares underlying the preferred stock. Each record holder of the depositary shares on the record date, which will be the same date as the record date for the underlying stock, will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the amount of the underlying stock represented by that holder&#146;s depositary shares. The depositary will then try, as far as practicable, to vote the number of shares of preferred stock underlying those depositary shares in accordance with those instructions, and we will agree to take all actions which may be deemed necessary by the depositary to enable the depositary to do so. The depositary will not vote the underlying shares to the extent it does not receive specific instructions from the holders of depositary shares underlying the preferred stock.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Conversion of Preferred Stock</i>. If the prospectus supplement relating to the depositary shares provides that the deposited preferred stock is convertible into or exchangeable for common stock or preferred stock of another series of BioCryst or securities of any third party, the following will apply. The depositary shares, as such, will not be convertible into or exchangeable for any securities of BioCryst or any third party. Rather, any holder of the depositary shares may surrender the related depositary receipts to the depositary with written instructions to instruct us to cause conversion or exchange of the preferred stock represented by the depositary shares into or for whole shares of common stock or shares of another series of preferred stock of BioCryst or securities of the relevant third party, as applicable. Upon receipt of those instructions and any amounts payable by the holder in connection with the </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">7</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">conversion or exchange, we will cause the conversion or exchange using the same procedures as those provided for conversion or exchange of the deposited preferred stock. If only some of the depositary shares are to be converted or exchanged, a new depositary receipt or receipts will be issued for any depositary shares not to be converted or exchanged.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Amendment and Termination of the Depositary Agreement</i>. The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may be amended at any time by agreement between us and the depositary. However, any amendment which materially and adversely alters the rights of the holders of depositary shares will not be effective unless the amendment has been approved by the holders of at least a majority of the depositary shares then outstanding. The deposit agreement may be terminated by us or by the depositary only if (a) all outstanding depositary shares have been redeemed or converted or exchanged for any other securities into which the underlying preferred stock is convertible or exchangeable or (b) there has been a final distribution of the underlying stock in connection with our liquidation, dissolution or winding up and the underlying stock has been distributed to the holders of depositary receipts.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Charges of Depositary</i>. We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangements. We will also pay charges of the depositary in connection with the initial deposit of the underlying stock and any redemption of the underlying stock. Holders of depositary receipts will pay other transfer and other taxes and governmental charges and those other charges, including a fee for any permitted withdrawal of shares of underlying stock upon surrender of depositary receipts, as are expressly provided in the deposit agreement to be for their accounts.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Reports</i>. The depositary will forward to holders of depositary receipts all reports and communications from us that we deliver to the depositary and that we are required to furnish to the holders of the underlying stock.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Limitation on Liability</i>. Neither we nor the depositary will be liable if either of us is prevented or delayed by law or any circumstance beyond our control in performing our respective obligations under the deposit agreement. Our obligations and those of the depositary will be limited to performance in good faith of our respective duties under the deposit agreement. Neither we nor the depositary will be obligated to prosecute or defend any legal proceeding in respect of any depositary shares or underlying stock unless satisfactory indemnity is furnished. We and the depositary may rely upon written advice of counsel or accountants, or upon information provided by persons presenting underlying stock for deposit, holders of depositary receipts or other persons believed to be competent and on documents believed to be genuine.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Resignation and Removal of Depositary</i>. The depositary may resign at any time by delivering notice to us of its election to resign. We may remove the depositary at any time. Any resignation or removal will take effect upon the appointment of a successor depositary and its acceptance of the appointment. The successor depositary must be appointed within 60 days after delivery of the notice of resignation or removal and must be a bank or trust company having its principal office in the United States and having a combined capital and surplus of at least $50,000,000.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">8</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pDPC"></a><b>DESCRIPTION OF STOCK PURCHASE CONTRACTS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following is a general description of the terms of the stock purchase contracts we may issue from time to time. Particular terms of any stock purchase contracts we offer will be described in the prospectus supplement relating to such stock purchase contracts. Material U.S. federal income tax considerations applicable to the stock purchase contracts will also be discussed in the applicable prospectus supplement. You should refer to the form of stock purchase contract and stock purchase certificate that we will file with the SEC in connection with the offering of the specific stock purchase contracts for more complete information.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may issue stock purchase contracts, including contracts obligating holders to purchase from us, and obligating us to sell to holders, a specified number of shares of common stock, preferred stock or depositary shares at a future date. The consideration per share of common stock, preferred stock or depositary shares may be fixed at the time that the stock purchase contracts are issued or may be determined by reference to a specific formula set forth in the stock purchase contracts. Any stock purchase contract may include anti-dilution provisions to adjust the number of shares issuable pursuant to such stock purchase contract upon the occurrence of certain events.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The applicable prospectus supplement will describe the terms of any stock purchase contracts in respect of which this prospectus is being delivered, including, to the extent applicable, the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">whether the stock purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities subject to purchase under the stock purchase contract, and the nature and amount of each of those securities, or the method of determining those amounts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">whether the stock purchase contracts are to be prepaid or not;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">whether the stock purchase contracts will be issued as part of a unit and, if so, the other securities comprising the unit;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">whether the stock purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance, or level of the securities subject to purchase under the stock purchase contract;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">any acceleration, cancellation, termination, or other provisions relating to the settlement of the stock purchase contracts; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">whether the stock purchase contracts will be issued in full registered or global form.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">9</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pDOW"></a><b>DESCRIPTION OF WARRANTS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may issue warrants to purchase our preferred stock, depositary shares or common stock or any combination thereof. Warrants may be issued independently or together with any other securities in the form of units, and may be attached to, or separate from, such securities. The terms of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the applicable prospectus supplement. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent. You should refer to the form of warrant agreement and warrant that we file with the SEC in connection with the offering of the specific warrants for more complete information.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The prospectus supplement will describe the terms of any warrants being offered, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the title and the aggregate number of warrants;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the price or prices at which the warrants will be issued;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the currency or currencies in which the price of the warrants will be payable;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the securities or other rights, including rights to receive payment in cash or securities based on the value, rate or price of one or more specified commodities, currencies, securities or indices, or any combination of the foregoing, purchasable upon exercise of the warrants;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the price at which, and the currency or currencies in which, the securities or other rights purchasable upon exercise of such warrants may be purchased;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the periods during which, and places at which, the warrants are exercisable;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the date or dates on which the warrants shall commence and the date or dates on which the warrants will expire;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the terms of any mandatory or optional call provisions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the price or prices, if any, at which the warrants may be redeemed at the option of the holder or will be redeemed upon expiration;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">whether the warrants will be sold separately or with other securities as part of a unit;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">if applicable, the date on and after which the warrants and the related securities will be separately transferable;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">any provisions for the adjustment of the number or amount of securities receivable upon exercise of warrants;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the identity of the warrant agent;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the exchanges, if any, on which the warrants may be listed;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the maximum or minimum number of warrants which may be exercised at any time;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">if applicable, a discussion of any material United States federal income tax considerations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">whether the warrants shall be issued in book-entry form; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">10</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pDOU"></a><b>DESCRIPTION OF UNITS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may issue units consisting of one or more of the other securities described in this prospectus in any combination, as described in a prospectus supplement. We may issue units in one or more series, which will be described in a prospectus supplement. We will issue the units or hybrid securities under one or more unit agreements, each referred to as a unit agreement, to be entered into between us and a bank or trust company, as unit agent. You should refer to the form of unit agreement and unit certificate that we file with the SEC in connection with the offering of the specific units for more complete information.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The applicable prospectus supplement will describe:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the designation and the terms of the units and of the securities constituting the units, including whether and under what circumstances the securities comprising the units may be traded separately;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any additional terms of the governing unit agreement;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">any additional provisions for the issuance, payment, settlement, transfer or exchange of the units or of the preferred stock, common stock, stock purchase contracts, depositary shares or warrants constituting the units; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any applicable United States federal income tax consequences.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">11</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 206-plan -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pPOD"></a><b>PLAN OF DISTRIBUTION</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may sell the securities being offered hereby at prices and under terms then prevailing, at prices related to the then current market price or in negotiated transactions from time to time in one or more of the following ways:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">directly to one or more purchasers;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">through one or more underwriters on a firm commitment or best-efforts basis;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">through broker-dealers, who may act as agents or principals, including a block trade in which a broker or dealer so engaged will attempt to sell as agent but may position and resell a portion of the block as principal to facilitate the transaction;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">through agents;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">through remarketing firms;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">in privately negotiated transactions; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">in any combination of these methods of sale.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We will set forth in a prospectus supplement the terms of the offering of securities, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the name or names of any underwriters, dealers or agents;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">the number of securities and purchase price of the securities being offered and the proceeds we will receive from the sale;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">any underwriting discounts and commissions or agency fees and other items constituting underwriters&#8217; or agents&#8217; compensation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any over-allotment options under which underwriters may purchase additional securities from us;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any delayed delivery arrangements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any discounts or concessions allowed or re-allowed or paid to dealers; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any securities exchange on which the securities may be listed.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The distribution of the securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices related to the prevailing market prices or at negotiated prices.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may designate agents who agree to use their reasonable efforts to solicit purchases for the period of their appointment or to sell securities on a continuing basis. Agents may receive compensation in the form of commissions, discounts or concessions from us. Agents may also receive compensation from the purchasers of the securities for whom they sell as principals. Each particular agent will receive compensation in amounts negotiated in connection with the sale, which might be in excess of customary commissions. Agents and any other participating broker-dealers may be deemed to be &#147;underwriters&#148; within the meaning of Section 2(11) of the Securities Act of 1933 (the &#147;Securities Act&#148;) in connection with sales of the securities. Accordingly, any commission, discount or concession received by them and any profit on the resale of the securities purchased by them may be deemed to be underwriting discounts or commissions under the Securities Act. We have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their securities. As of the date of this prospectus, there are no special selling arrangements between any broker-dealer or other person and us. No period of time has been fixed within which the securities will be offered or sold.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If required under applicable state securities laws, we will sell the securities only through registered or licensed brokers or dealers. In addition, in some states, we may not sell securities unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and complied with.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we use underwriters for a sale of securities, the underwriters will acquire the securities for their own account. The underwriters may resell the securities in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may change from time to time any initial public offering price and any discounts or concessions the underwriters allow </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">12</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">or re-allow or pay to dealers. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement naming the underwriter the nature of any such relationship.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may use a remarketing firm to offer to sell the securities in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own account or as agents for us. These remarketing firms will offer or sell the securities pursuant to the terms of the securities. A prospectus supplement will identify any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm&#146;s compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we offer and sell securities through a dealer, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. Any such dealer may be deemed to be an underwriter of the securities so offered and sold. The name of the dealer and the terms of the transactions will be set forth in the applicable prospectus supplement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may also sell securities directly to one or more purchasers without using underwriters or agents. Underwriters, dealers and agents that participate in the distribution of the securities may be underwriters as defined in the Securities Act and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We will identify in the applicable prospectus supplement any underwriters, dealers or agents and will describe their compensation. We may have agreements with the underwriters, dealers and agents to indemnify them against specified civil liabilities, including liabilities under the Securities Act. Underwriters, dealers and agents may engage in transactions with or perform services for us in the ordinary course of their businesses.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may authorize agents, dealers or underwriters to solicit offers to purchase securities at the public offering price under delayed delivery contracts. The terms of these delayed delivery contracts, including when payment for and delivery of the securities sold will be made under the contracts and any conditions to each party&#146;s performance set forth in the contracts, will be described in the applicable prospectus supplement. The compensation received by underwriters, agents or dealers soliciting purchases of securities under delayed delivery contracts will be described in the applicable prospectus supplement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may enter into derivative or other hedging transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. We may also loan or pledge securities covered by this prospectus and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless otherwise specified in the related prospectus supplement, all securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We may apply to list any series of securities on an exchange, but we are not obligated to do so. Therefore, no assurance can be given as to the liquidity of, or the trading market for, any series of securities.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on The NASDAQ Global Select Market or otherwise.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any underwriters who are qualified market makers on The NASDAQ Global Select Market may engage in passive market making transactions in the common stock on The NASDAQ Global Select Market in accordance with Rule 103 of Regulation M, during the business day before the pricing of the offering, before the commencement of </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">13</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We will bear all costs, expenses and fees in connection with the registration of the securities, as well as the expense of all commissions and discounts, if any, attributable to sales of the securities by us.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">14</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pLM"></a><b>LEGAL MATTERS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Gibson, Dunn &amp; Crutcher LLP has rendered an opinion with respect to the validity of the securities being offered by this prospectus. We have filed this opinion as an exhibit to the registration statement of which this prospectus is a part. If counsel for any underwriters passes on legal matters in connection with an offering made by this prospectus, we will name that counsel in the prospectus supplement relating to that offering.</p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pEXP"></a><b>EXPERTS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016, and the effectiveness of our internal control over financial reporting as of December 31, 2016, as set forth in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements and our management&#146;s assessment of the effectiveness of internal control over financial reporting as of December 31, 2016 are incorporated by reference in reliance on Ernst &amp; Young LLP&#146;s reports, given on their authority as experts in accounting and auditing.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">15</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pWFI"></a><b>WHERE YOU CAN FIND MORE INFORMATION</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We file electronically with the SEC our annual reports on Form 10-K, quarterly interim reports on Form 10-Q, current reports on Form 8-K, proxy statements and other information. We make available on or through our website, http://www.biocryst.com, free of charge, copies of these filings as soon as reasonably practicable after we electronically file them with or furnish them to the SEC. The information on our website is not incorporated by reference into this prospectus. You can also request copies of such documents by contacting our Investor Relations Department at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703 or sending an email to investorrelations@biocryst.com. You may read and copy any document we file at the SEC&#146;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You can also obtain copies of this information by mail from the Public Reference Room of the SEC at prescribed rates. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The SEC also maintains an Internet site that contains reports, proxy and information statements, and other information about issuers, like BioCryst, that file electronically with the SEC. The address of that site is http://www.sec.gov. Unless specifically listed below under &#147;Incorporation of Certain Documents by Reference&#148; the information contained on the SEC website is not incorporated by reference into this prospectus.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have filed with the SEC a registration statement on Form S-3 that registers the securities we are offering. The registration statement, including the attached exhibits and schedules, contains additional relevant information about us and our securities. The rules and regulations of the SEC allow us to omit certain information included in the registration statement from this prospectus.</p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="pICR"></a><b>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus, except for any information that is superseded by information that is included directly in this document.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus includes by reference the documents listed below that we have previously filed with the SEC and that are not included in or delivered with this document. They contain important information about us and our financial condition.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">Our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001159/f10k_022717p.htm">February 27, 2017</a> (including the sections of our proxy statement relating to our <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317002085/def14a_041217.htm">May 24, 2017</a> annual meeting of stockholders that are incorporated by reference therein);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">Our Quarterly Reports on Form 10-Q for the quarters ended <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317002784/f10q_050817p.htm">March 31, 2017</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317004830/f10q_080817p.htm">June 30, 2017</a> and <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317006746/f10q_110817p.htm">September 30, 2017</a>;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">Our Current Reports on Form 8-K filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001135/f8k_022717.htm">February 27, 2017</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001519/f8k_031517.htm">March 15, 2017</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001617/f8k_031717.htm">March 17, 2017</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317003361/f8k_053017.htm">May 30, 2017</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317004572/f8k_080217.htm">August 2, 2017</a> and <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317005555/f8k_091517.htm">September 15, 2017</a>; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; ">The description of our common stock which is contained in our Registration Statement on Form 8-A (File No. 000-23186) filed with the SEC on January 7, 1994, together with the amendment thereto filed with the SEC on March 14, 1994, including any other amendment or reports filed for the purpose of updating such description.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All documents filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of the registration statement of which this prospectus forms a part and prior to the effectiveness of such registration statement and on or after the date of this prospectus and prior to the termination of our offering of securities shall be deemed to be incorporated by reference herein and to be a part of this prospectus from the date of filing of such documents, excluding any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K and exhibits filed on such form that are related to such items. Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">16</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">You can obtain any of the documents incorporated by reference in this prospectus from us without charge, excluding any exhibits to those documents unless the exhibit is specifically incorporated by reference as an exhibit to this prospectus. You can obtain documents incorporated by reference in this prospectus at no cost by requesting them in writing or by telephone from us at the following address:</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Investor Relations<br>BioCryst Pharmaceuticals, Inc.<br>4505 Emperor Blvd., Suite 200<br>Durham, North Carolina 27703<br>(919) 859-1302</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have not authorized anyone else to make additional representations or to provide you with information other than information provided or incorporated by reference in this prospectus or any prospectus supplement. We take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you or representations that others may make. If you are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this document are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this document does not extend to you.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">17</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 300-bcv -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-frill" style="width: 100%; margin-left: 0%; ">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>

<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; line-height: 22px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Pre-Funded Warrants<br> </b></i><i><b>to Purchase 11,764,706 Shares of Common Stock</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 96px; margin-bottom: 0px; "><img src="logo_biocryst2a.jpg" alt="" style="height: 152.53px; width: 375.47px; scale: ">&#8201;<br> </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">&#8201;</p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 64px; margin-bottom: 0px; "><b>Prospectus Supplement</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 288px; margin-bottom: 0px; ">November 19, 2019</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>



<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>



<div class="block-pagebreak" style="width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_biocryst2a.jpg
<TEXT>
begin 644 logo_biocryst2a.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( 7X#J@,!(@ "$0$#$0'_Q  ?  $  0,% 0$
M    "0@*"P$"!08'! /_Q !I$  ! P,"! (& P@*#0<)! L!  (#! 41!@<(
M$B$Q$T$)%")187$*@9$5(S)R=:&QM!8U-D)2DK*UT? S-SA58G-T=I7!T^'Q
M%Q@9)#1#LQHE*#E35EB#E":BIM)%1D=78V5F@J3$U/_$ !T! 0 " @,! 0
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M41$2E$1$I1$1*41$2E$1$I47W_27Z0_]U)?_ *M_^S3_ *2_2'_NI+_]6_\
MV:AQR?A]@_H3/R^P?T*I_P#:K6O][%V_JE_9_P C^/V^,?\ \8>.O_U*U_\
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M(E*(B)2BVN<&@N<0 T$DDX  [DD]!@>]:N<&@N<0  223@ #N2>PP%&_Q?\
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M$/:UDLO,#SAF,=/+MCIY=/BNBV-F(KCYPK-*5_4%<[''NV!YMR6R,;5H;1K
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M=.NWM=??M4QT7Y6.#=9=81?MIUPY"K%J49MPQ/83Y:WS[C*">PJ0=%PUDO\
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M*,ED D V&<\A8C&>I^-9FH< \8:7$T]YH-^L2;O)"B7*JH /,?F[RE0 3EB
M-NO6J8,^\ _, _7U7-Z=U+?])W*"[:;NU5:KA3O$D<L4TACRT@X,(<&'.,8(
M7#S0S4\KX*F":FGC<6R0U$3X7M<#@@-D#2['P'Z5^:UBDJP92593D,"58'U!
M&""/PQ[JB<<DL$BR1N\4L; JZ,T<D;J>JLI#(P(ZC<5,!PT<=;+U44&C=UI&
MTMQ?R4]'?Y".2K.,#GC8WECQ[+<N()\\J4FFJ8*R"*JI98YZ>>-LD4L3VO8]
MCVAS2'-)!R"/-6FX.,8+FEKFO8]CBQ['M/,US7M]H8=@]"/Z96N"#BFJFU5+
MM1KNXF9LF(M.7&I?CHW+I(WO=DG'1K>=W?MYJ></\2.\B6.H/S,V%M[DXRS;
M 1RG;)/T7ZD['UKT=\F7RJSW%Q;\/<2S^*TQ6'3]4D($ADV"6UVW1BY\L4Y\
MS-A7R3S5+JN&OUCMVH[376>Z4\5515T$D$T4K ]I\1A8UV"#U:3D?%<NUP>U
MKVD%K@'-(Z@M(R"/F""MRG1 8$$ @C!!W!![&O1CHDB,CJKHZE65@"K*PP5(
M.Q!!P1W%6X/$]LA5[*;AUM!#&YVF[Q42SV6IY"(QD^+.P>[E<[EP<?#HJ;5<
M+<8FSE-NGMA<98(.>_6*%U3;)6LYI&M!\2HP1U.6-.>A\^BM[)(Y(I)896ED
ML$TM/(P@@A\#S&[.?>6JIN(=,&FWS"-<6]QF6'T7?SQ_]#'8?5*UXG^4WA(<
M*\12);(5TS40UW8_5C!;$]L#_P!S(?*/]VZ>E;$1%H:KFB(B4HB(E*(B)2B(
MB4HB(E*(B)2B(B4HB(E*(B)2B(B4I[NI!!#FN:>5S7-ZM<UPZ@@X/0C.%)9P
M?<8-3I&IH=N=QJY\]@G>V"SWB=SG&A)..1_=[^=Y:P<[L ?%1IK4'&,$@AP<
MUS3RN:YO5I:X=1@X/3OA9EA?W&G7*W-NV&&SH<\DB'&4<9Z'&QZ@[C!Z[_AO
MB34^%]3AU/3)BDB$+-"Q)@NH,CF@G7(!4CV6]J-L,I&]78U)5TU?30UE'-'4
M4U1&R6&:)[7L>Q[0YI#FDCL1D9R#T/5?2H7.#[C J=(U-#MQN/7/GL,[VP6>
M\3N+C0EQ_!D[ND;(XA@<YV&CY!3-TE735]-#64<T=135$;)89HGMD8]DC0YI
M#FD@Y!'GT5M:9J=OJEN)H6PXP)HB?/$^-P1]4]5;H1[\U[6X1XNTSB_3$OK%
MPDR!4O;)V!FM)B,E' ]J-NL<@\KKZ$$#Z$1%LJE=$1$I1$1*41$2E$1$I1$1
M*41$2E$1$I1$1*41$2E$1$I1$1*41$2E$1$I1$1*41$2E$1$I1$1*41$2E$1
M$I1$1*41$2E$1$I1$1*41$2E$1$I1$1*5:7HB*AZ_-^B[CH/0U_W%U1;=*:;
MI9:FXW&4,YF-);3Q@CGD>XCD&&9< X@G'1=.[8_PG-8WXO>0U@^MQ"F^X#-C
M(-'Z+;KZ\TL;K]J1K9(3*QIDI&1.<&EA(R.=A!) !Q\EM=&TUM4O4@R1$OGG
M<=5C!&P_:;.!]I[5,^!.$Y>+]>@T[+1V<2_.=0G4;QVJ,H**>TDY(CC],E^B
MFO5.'OA+T1L];*2MK*2GO>JY(HY*NYU$+7-;*YH/*() Y@+"2W(&3C/N57;(
MXXV!D;&1L'0-C:(VCY-;@#ZEO[(K<MK6"TB6&WB6*-1@!1UV RQZLQQN3DDU
M[:TG1].T.SBL-,M(;2VA4*J1* 20 "TC^U([$99W)9CN33&/^)/Z5ICY_:?Z
M5JB[ZV==/U?H32^N+556?4=GH[A25<;HW\\$8E&0<%LV/$&#@^RX94('%5PE
MW#9RIFU5I9LM?HRJE?)+%&QQ-JYG= 3UDD#WNQ[FA3WKK6KM+VG6.G[GI^\T
MD=917"EEB?'( 0'NC+8W#(."UQ#NGN6HU?2+?5(&5E5+A03#,!YE;J Q&"R$
M[,I/OZU!N-N!],XOTZ6.6&.'4XHV-C?J@$L4F,JDA&#) Y #QMD ;KAMZM5/
MZ_[OF/,>2+UW?';*MVEW(O\ I*I8[U:&I=-;Y<8;)%4$S<K?+#&N [XZ+R)5
M%+$\$LD,@Y9(G:-U]&4X(_R]1O7B*]L[C3[RYL;I#'<VD\EO/&W59(F*L/>,
MC(/0@@C8U6#P9[SU.UVYU%::VL=%IG4T@@KHW./A12,'+#R@]&\TCL^SCKW)
M[*X*@F9400U$9#HYXHYHR#D%DC ]I!^((5IS#42TD]-5P.<R>EJJ>HC>TD%O
MA2MD.,8([>]7*/#7KH[A;0:4U!),)*F2E-/..;F</5<0MS\PT8^7UJ><'7[.
MD^GR-GP@)H<D^P2!(HSV#$,![S7H_P"0KB.2:#4.&KB0N+4?/['F;/+#(P2Y
MB7.X5)"L@ VS(W0;U[TNNZN_<Q?OR37_ *K*NQ+KNKOW,7[\DU_ZK*IL_L-^
MZWY&O0-Q_-Y_X,O]AJM:-0?M_?/RO</UJ1<0N7U!^W]\_*]P_6I%Q"HM_;;]
MYOS-?G5/_+S?Q9/[9KG=+_NHTY^5:+]:B5TWI[]H+)^2;=^J0JUDTO\ NHTY
M^5:+]:B5TWI[]H+)^2;=^J0J=\%=+_XP?E)7HWY /9XF_>TW^[GKF%\=PK8;
M=15==4/;'#24\U1(Y[@UH;#&Z0C)]X:5]BI-XRMPCH+9?4,U+(8KC<(HX*4M
M=RO+7OY)>7SSRG!P>W?HII=3K:V\UP_LPQO(>V>52<?$]!5^:QJ46D:5J&IS
M$"*QM9KEL]_"0L%'O8@*/4D5#CQ1;PUN[NY]WK&U+W6"SU+Z>STW.XQ,+28I
MR!V.7-YCGL>RIO6N7'G<\ESY9))W./<NF<9#U[GJ[W]?@M%2EQ/)=3RW$K%I
M)G:1B3GVN@'[(& !Z5X!U34;G5]0O-2O',ES>SO/(Q)."YRJ#/1(UPB ;!5
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M7EQ;X/U8Y"$(]S(58'N""*[WMC>H]/[B:1O4QY8J2X11O.<8\::-@)(QCO\
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M\&RF<;8YAO[J\Q:K\AO$UIS-IMW8:I&#LO,]I<$?N2\\6?\ XH&_W0D(J_\
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M7-,,7-SRR2CZB@>2/XJ"2W[1(Z 5[.^2O@Y^%M!\6]3DU352ES=(1YH(@O\
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MI;3;B[DZZW9U====;CZGNFK-57JJDK*^X7&KJ)X72RN+R(:6:62*$-+BT",
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MRH!(ZY-<S6:CU+<9'S7+5>K*V5Y)>^74EW=S$]^CJMW0]>A]ZXSUBJ_OM?\
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M[=]K9Q*/W?W N.N'V8Z:^Y9KR\FC\9\@EY.9[_PP.O8J\*).3U^PG'U*R/\
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M>ML5WI*9O//4VZLAA;G'-))3R,8,_%Q 7RWLM^Z?RKJG!,$P R3%( !U)*$
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M:YCVAS7 M<UPR"TC!!!Z=1T4<?%/P64.OS6:WV\ACMVJFM=-56^)H;'<RT=
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M<M8:CHH67"G;)<J,4='6P.N#I:BFC=3QM-/S_AR-R#@967F#,?OG?621]A7
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M2BB?-427"[T%*^..-I<X^'/41NY@&GH 2?)?8!8X )/H!D_<*["0HR2% ]2
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MNF6UOC$G())3W,K@,V<=<$X'N ':O/\ Q'J3:GJEQ-DF-7*1C?95\HV(!4D
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MZ+SPX[W55[UIPWW?_D8U=5NJ*U]NCIYKK35]7)SR%C6S2LBI@Z0G'*WE =\
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M1YGH.4%W7_!&?SJ\_P#HJ7 F+_JK5O&/KBSNC@LWJT>V=54TY<R4S,EHKFZ
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M"C:(ZX!#OQ2'#[0F#[C]A7W/:VUR.6X@BF'I(BN/Q!]!75!?7EK_ #>XEA.
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M5Q<)2Z;'IL4%M<1M<'];<J2%E\1@.;*M@E5V0,!@X&,U2_&4&J3:D\TUO(L
M(2WQYEY!LO*0.K8YRH+%<G."<#Q^BKJZVU#*RV7*Z6JKB<'Q3VNXU=O+7M.6
MG%++%G!ZJO'8[TH/';P[&E&V6_=[HJ6DY/"HKBQUU]EN &&2NEE)Z=,D_-4!
MM+79PYK<$^S(1'(/G&_#@?@1GX+7!S@=?EU^'DI/-;6]PO+/#%,OI(BN#]C
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MI7>K:2^5EJO5@N$,]PH()G-IKO1%[&U4-1"7"!__ %8/:TO8XM+LMQ@+*/\
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M]VFD-(:EUWJ6S:/T?9JW4&IM05L%!:K5002SS3S3RLA#G"%CS&R,O#G.< ,
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MV!;%^D44T\C(8(99YI'89%#&^21[B>P:P.)ZGJ<+F;EI?4MGA94W6QU]%32
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M*VHKI?O#"QGA>LEQBRTD.\,CF_?*1L -&![R?M4)XDUP:U<Q/$)$MH4Q&D@
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H2E$1$I1$1*41$2E$1$I1$1*41$2E$1$I1$1*41$2E$1$I1$1*5__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
